Trans-species Transcriptomic Comparison of in vitro and in vivo Neural Cells by LoVerso, Peter
Rochester Institute of Technology
RIT Scholar Works
Theses Thesis/Dissertation Collections
4-30-2015
Trans-species Transcriptomic Comparison of in
vitro and in vivo Neural Cells
Peter LoVerso
Follow this and additional works at: http://scholarworks.rit.edu/theses
This Thesis is brought to you for free and open access by the Thesis/Dissertation Collections at RIT Scholar Works. It has been accepted for inclusion
in Theses by an authorized administrator of RIT Scholar Works. For more information, please contact ritscholarworks@rit.edu.
Recommended Citation
LoVerso, Peter, "Trans-species Transcriptomic Comparison of in vitro and in vivo Neural Cells" (2015). Thesis. Rochester Institute of
Technology. Accessed from
Trans-species
Transcriptomic Comparison
of in vitro and in vivo Neural
Cells
Peter LoVerso
A Thesis submitted in partial fulfillment of the requirements for the
degree of
Master of Science in Bioinformatics
Department of Bioinformatics
College of Science
Rochester Institute of Technology
Rochester, NY
April 30 2015
1
Rochester Institute of Technology
Thomas H. Gosnell School of Life Sciences
Bioinformatics Program
To:     Head, Thomas H. Gosnell School of Life Sciences
The undersigned state that Peter LoVerso, a candidate for the Master of Science 
degree in Bioinformatics, has submitted his thesis and has satisfactorily defended 
it.
This completes the requirements for the Master of Science degree in 
Bioinformatics at Rochester Institute of Technology.
Thesis committee members:
Name Date
________________________________________ _______________
Feng Cui, Ph.D.
Thesis Advisor
________________________________________ _______________
Gary R. Skuse, Ph.D.
________________________________________ _______________
Gregory Babbitt, Ph.D.
Contents
Section 1: Abstract.............................................................................................3
Section 2: Introduction......................................................................................4
Section 3: Methods...........................................................................................10
Section 4: Results.............................................................................................32
Section 5: Discussion and Future Work...........................................................80
Section 6: References.......................................................................................83
2
Section 1
Abstract: Trans-species Transcriptomic Comparison of in vitro and in vivo Neural Cells
RNAseq has recently evolved into a powerful tool for the analysis and comparison of 
different cell types within and across organisms, and allows for accurate, reproducible 
measurements of the transcriptome of these cells. Here, RNA from three different neural cells 
types (oligodendrocyte progenitor cells, neurons, and astrocytes) in rats (R. norvegicus) are 
grown in vitro then sequenced and aligned to the rn5 genome assembly. Furthermore, RNA from 
two different human (H. sapiens) neural cell types (neurons and astrocytes) grown in vitro were 
also sequenced and aligned to the hg38 assembly. An in vivo dataset of RNAseq reads was 
identified from literature, containing data for all three cell types in mice. These reads were 
aligned to the mm10 genome assembly, the annotation of which was then converted into its 
orthologous coordinates for rnor5 and hg38. The expression of all data was then quantified in 
terms of the mouse annotation, normalized, and compared to determine differences in expression.
Differential gene expression and pathway analysis across these data have identified a 
number of pathways and genes which are significantly differently expressed and enriched in in 
vivo cells as compared to in vitro, as well as specific differences between cell types, showing that
especially when targeting certain diseases in vitro cells should not be used as a drop-in 
replacement for in vivo. Similarities and differences were also observed between this RNA-seq 
data and the microarray data presented in previous in vitro/in vivo studies involving the same 
cell types and species. These data are presented and discussed along with the first comprehensive
protocol for comparing RNAseq data between species.
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Section 2
Introduction: Applications of next-generation sequencing in neural cells and neurological
diseases
Neural tissue constitutes one of the most complex types of tissues in mammals, and 
despite being the subject of a great deal of study over the years, is still somewhat poorly 
understood. The brain consists of many different cell types with varied unique roles, all of which 
are crucial for proper brain function. By studying these discrete cell types and how they relate to 
one another, a better understanding of how the brain functions as a system can be elucidated. 
This in turn can then be directly applied to facilitate a better understanding of various 
neurological diseases, aiding in both diagnosis and treatment.
Recently, with the advent of next-generation sequencing, it has been possible to perform 
whole exome sequencing on a per-cell basis [Tang et al., 2010], allowing high-fidelity 
examination of biological tissues, and enabling the quantification of the differences between 
different tissue types, whether between different types of healthy tissue, or comparing healthy 
tissue to diseased tissue. Over time, as the size of these datasets build up, comprehensive 
transcriptomic profiles can be built of different types of cells against which new data can be 
compared. These can be used to diagnose diseases, assess success and effects of various drugs or 
genetic modifications, and allow for personalized treatment of cancers and disorders targeted 
against the expression of the affected individual.
One particular region of interest in these studies is the brain, which is among the most 
important organs in the human body. It has been the subject of a great deal of research, due to its 
importance relating to human intelligence, in which it plays a star role. It is also the root of a 
number of unpleasant diseases, including Huntington's Disease and Alzheimer's Disease, and 
volumes of research have been published on the causes and effects of these and other diseases. 
The brain is also one of the more difficult organs to study, especially in humans, due to the 
difficulty and risk involved in taking comprehensive biopsies from living specimens. For these 
and other reasons, the brain continues to be a hot area of research in the treatment of cancers and 
other diseases as well as for possible targets for positive genetic engineering.
A) Biological significance of neural tissue
The brain is made up of a large number of different cell types, with discrete functions 
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which are all vital to the proper function of the central and peripheral nervous systems. Foremost
among these is the neuron, the primary vehicle for long-distance electrical communication and 
computation among cells in mammals. Neurons are interconnected cells which carry electrical 
signals from all over the mammalian body to the central nervous system (CNS) and back, and 
which process that information within the CNS to determine which signals are appropriate to 
send next. They are arguably the most important cell type in the body, enabling the computations 
required for important behaviors such as balance, communication, and the ability to learn and 
make decisions. Neurons send signals amongst themselves by means of changing electrical 
potentials using a chemical gradient across the cell membrane, which can proliferate along the 
axon of the cell to the synapse at the end, where neurotransmitters are released in accordance 
with the nature of the electrical signal, stimulating the receiving neuron to modulate its own 
electrical potential accordingly.
The genes expressed in a neuron are extremely important for its proper functioning, 
modulating the production, transport, release, and uptake of neurotransmitters among many other
tasks. Changes in gene expression of neurons can lead to over- or under-expression of important 
proteins, changing their levels in and around the cell, which can radically change the overall 
topology of the nervous system and lead to severe disorders. For example, Parkinson's Disease is
characterized by accumulation in certain cells of alpha-synuclein and a subsequent deficiency of 
dopamine in the brain as the cells producing it die, and Huntington's Disease is caused by the 
production and accumulation of mutant Htt protein.
Neurons, capable as they are, cannot function properly without an extensive support 
network of non-neuronal cells which provide a variety of auxiliary functions including physical 
support, homeostatic regulation, and providing nutrients. Glial cells such as astrocytes and 
oligodendrocytes fill this niche, performing essential roles without which the mammalian 
nervous system would collapse. Astrocytes are star-shaped cells, with a number of important 
functions within the central nervous system. They provide a physical support network to the 
neurons, giving them a structure to hold them in place and facilitate their growth of connections. 
They hold important stores of glycogen, providing the surrounding cells with glucose as needed. 
They interact with the synapses of neurons, and work to both produce and remove 
neurotransmitters and other necessary compounds from the intercellular areas. Oligodendrocyte 
progenitor cells are precursor cells which are involved in the production of oligodendrocytes, 
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which are the cells partially responsible for the production and maintenance of myelin in the 
central nervous system.
B) The uses of next-generation sequencing
Next-generation sequencing (NGS) to quantify, analyze, and compare biological tissue 
has become an invaluable tool for biological scientists in recent years, allowing for accurate, 
reproducible measurements of transcriptomics. While other methods of quantifying the exome of
a particular cell or tissue, such as microarrays have been around for many years, they frequently 
have many limitations.  Microarrays can have cross-hybridization artifacts, detection difficulties 
due to the dye, and can be very limited in terms of alternative splicing [Mortazavi et al., 2008]. 
These constraints make it difficult to comprehensively find and analyze all RNA molecules 
which may be relevant to a given experiment, and comparison between experiments can be 
problematic due to the analog nature of the data signals [Schena et al., 1995]. New sequencing 
technologies have the capacity to deliver sequencing results for trillions of base pairs in under 
three days, from a single machine [Illumina Spec. Hiseq X Ten, 2015]. These sequencers can be 
used together with other techniques to comprehensively sequence all of the RNA present within a
cell after the generation of cDNA, allowing for the accurate counting of the numbers of 
molecules present in the cell. Depending on the preparation of the sample, RNA-seq samples can
be prepared for generalized cell types, for specific tissue regions, or even for individual cells 
[Tang et al., 2010].
The general process for RNAseq is as follows. First, the cells with the desired conditions 
are prepared and isolated. The RNA is isolated from these cell(s) using one of the available 
published techniques, and is treated to remove any contaminating genomic DNA that may have 
been present, as well as to remove as much rRNA as possible. Ribosomal RNA is by far the most
common RNA present in the cell, but generally from the view of the RNAseq experiment, is 
some of the least interesting. As the purpose of most RNAseq analyses is to examine differences 
in expression between treatment types, mRNA is generally the target for the sequencing, and 
sometimes other RNAs such as siRNA. The removal of rRNA will reduce the amount of noise in 
the final product, as well as reducing the amount of sequencing necessary to yield the desired 
level of mRNA counts. The RNA content levels can be optimized in this way through either the 
removal of the rRNA, or the selective enrichment of the mRNA [Wilhelm et al., 2010]. The 
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isolated RNA is then reverse transcribed to form cDNA, which can be fragmented and sequenced
on a high-throughput sequencer.
The sequencer will return a data file, often in FASTQ format, which describes all of the 
reads, or individual nucleic acid molecules, which were sequenced. The base pair sequence for 
each read is reported, as well as a quality score at each position and some other metadata. Many 
sequencers will perform their own rudimentary quality control, indicating in the output file 
whether or not a read meets a quality threshold or should be discarded. A bioinformaticist may 
wish to run further quality control on the output as well- if, for example, numerous samples were
run at once, the molecules may have been barcoded, and the output may need to be 
demultiplexed and the barcodes trimmed. Tools such as FastQC may be useful in assessing 
quality. Once the researcher is satisfied with the quality of their raw data, the reads are aligned to
a reference genome. A number of sources for reference genomes exist- one excellent example is 
the University of California, Santa Cruz (UCSC), which has published reference genomes and 
annotations for dozens of species. A short read aligner such as SHRiMP, Bowtie/Tophat, GSNAP,
or others are used to do this. The different aligners have various features which make them more 
or less appropriate for different sorts of analyses, and the researcher may choose different tools 
based on which they deem most appropriate. Differences between the aligners include statistical 
models for alignment, treatment of potential splicing sites, and handling of ties for alignment 
locations. Alignment software may also have features allowing for further quality control.
The aligned reads are generally output in Sequence Alignment/Map (SAM) format [Li et 
al., 2009], which is a somewhat human-readable format showing the location, base pair 
sequence, and alignment quality of the input reads. They are often then converted into BAM 
format, which is a compressed binary version of the SAM data. BAM files can also be sorted and
indexed for significant performance gains. Following alignment, reads are matched up against an
annotation to quantify which gene each read belongs to, and then provide either raw counts, or 
normalized counts in the form of FPKM or similar, which may be used for comparisons of the 
data to other treatments.
Unlike microarrays which use linear models to assess differential expression of genes 
between samples [Smyth et al., 2004], most popular differential expression analysis software for 
RNAseq uses a negative binomial dispersion to estimate distributions of reads, a technique that is
also used with serial analysis of gene expression (SAGE) experiments [Robinson et al., 2008]. 
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Poisson distributions have also been used in some cases. These distributions are used to generate 
lists of differentially expressed genes between the samples in question, which can then be tested 
for enriched categories/pathways from the Gene Ontology, KEGG, or other sources which take 
the list of genes and allows a more broad biological insight into the differences between the 
samples being tested [Oshlack et al., 2010]. For both RNAseq and microarray experiments, large 
numbers of tools have been published which will perform this gene enrichment [Nam et al., 
2008]. Several of those tools which are geared towards RNAseq will be discussed in the 
Methods.
D) Application of NGS to medical science
The ability to quantitatively compare the transcriptomes of two different groups is 
immensely valuable and has far-reaching implications for biological understanding and the 
treatment of disease. By comparing a diseased cell or tissue to a healthy sample of the same, the 
exact effects of the disease can be quantified and shown compared to what is healthy, and 
analysis of these differences may even yield the root cause of the disease. The differences 
between cells may be shown by isolating samples of healthy tissue and comparing expression 
profiles of different cell types. When testing a new drug, or other treatment for some disease, 
treated cells or tissues may be compared against controls to examine any possible undesirable 
side-effects. Furthermore, when examining a disease of some sort, diseases which may outwardly
appear to have identical symptoms can turn out to have in fact very different transcriptome 
profiles, and respond very differently to certain treatments. In this way, and others, the 
applications of RNAseq and other next-generation technologies combined with the quickly 
falling costs of sequencing large amounts of nucleic acid hold enormous promise for the 
personalization of medicine and the customizability of treatments for many conditions.
Other applications involve the assessment of the probable accuracy of certain treatments 
or research paths that may be less suitable than previously thought. For example, research is 
commonly done on in vitro cells, because the logistics and expense of maintaining and 
controlling a source of in vivo cells may be too much for many places. However, cells which are 
grown in vitro may express certain genes or pathways differently than the same cell taken 
directly from the organism in question, and if these cells are then treated with a drug intended to 
treat some sort of condition, then the response to that drug may well differ depending on whether
they were raised in vitro or in vivo. If two cells were compared in vitro against in vivo, and 
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pathways involved in particular diseases were found to be significantly different between the 
two, then it might well be that a treatment for that condition, especially one involving that 
particular part of the pathway, should be tested on in vivo cells rather than in vitro despite an 
additional cost, as the in vitro conditions do not mimic those within the organism closely enough 
to extrapolate results to a complete organism from a petri dish.
E) Prior work
A large body of research has been published regarding transciptomics in neural tissue in 
humans, rats, and mice, although a study of the exact sort as this has not previously been done. A
selection of published works which were particularly helpful or relevant to this experiment have 
been summarized below, sorted by publication date.
Paper Summary of relevance
Dugas et al., 2006 Compared OPCs and oligodendrocytes in rats using microarrays. 
Included a comparison of in vivo OPCs to in vitro OPCs, reporting 
similarity of expression especially in myelin-related genes
Lovatt et al., 2007 Compared astrocytes and neurons in vivo in mice using microarrays
Cahoy et al., 2008 Published a comprehensive transcriptome analysis of astrocytes, 
neurons, and oligodendrocytes in vivo in mice using microarrays. 
Also performed a comparison of in vitro astrocytes to in vivo, 
reporting on the Notch pathway and top enriched genes.
Miller et al., 2010 Meta-analysis examining differences in expression in astrocytes, 
neurons, and OPCs between mice and humans based on microarray 
data from other studies. Focused specifically on Alzheimer's related
genes and pathways. Used similarity of gene networks to determine
which genes to compare betwene species.
Rowitch et al., 2010 Reported on the developmental genetics of a number of different 
stages and types of neural stem cells, especially with regard to glia 
and OPCs.
Liu et al., 2011 Compared RNAseq and microarray data between humans, 
chimpanzees, and rhesus monkeys based on pairwise genome 
alignments. This paper formed the basis of the cross-species 
protocol used.
Zhang et al., 2014 Generated an RNAseq database for astrocytes, neurons, and OPCs 
in vivo in mice, among other cell types as well, to create a database 
of splicing in these transcriptomes. It is this study which provided 
the mouse RNAseq data used to be compared against the in vitro 
data.
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Section 3
Methods: A computational pipeline for RNA-seq pathway analysis between similar cells in
different species.
Description and Uses of the protocol
This protocol addresses a number of common needs in the processing of RNA-seq data, 
including alignment to a genome, quantification of gene expression based on an annotation, 
lifting of annotations between species to their best orthologues, differential expression analysis 
between multiple species and between multiple samples of one species, and pathway enrichment 
and analysis of differentially expressed genes. While many different protocols already exist for 
the alignment of reads to a genome, the quantification of expression, and differential expression 
analysis, the vast majority of these protocols only deal with the comparison of samples within a 
single species, and cannot be used with multiple annotations. Quantifications of differences in 
expression between species have a number of important applications to the field. Non-human 
mammal models are used for many medical treatment tests, and differences in pathways or 
annotation completeness can cause important information to be overlooked. Furthermore, meta-
analyses of several studies where similar treatments have been applied to a variety of species, a 
comparison between species based upon one particular reference is an excellent way to evaluate 
the frequency of various reactions to the treatment.
RNA-seq analysis typically begins with the sequencing of many individual cDNA reads, 
which are usually no more than several hundred base pairs long. The sequencer assesses the 
quality the sequencing of each base pair in each read, and returns the read and its quality along 
with some other metadata in a file. The scientist then examines this file, and may assess the 
overall quality of the data and use other tools to improve the average quality. Other operations 
are often performed in this step as well, such as the demultiplexing of barcoded samples which 
were sequenced together. At the end of the quality control process, the file with the high-quality 
reads is then the starting point for this protocol.
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The reads are then aligned to the genome of the organism whence they came using 
SHRiMP [Rumble et al., 2009]. This part of the protocol is dependent upon input data, and is not 
significantly distinct from many other methods of sequencing- it can easily be exchanged for 
another alignment platform of the user's preference (Tophat [Trapnell et al., 2009], GSNAP [Wu 
et al., 2010], or others). The output of many sequencing programs is in the Sequence 
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Figure 3-1: A flowchart showing the general analysis pathway from start to finish
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Alignment/Map (SAM) format [Li et al., 2009], and is then converted to a binary format for 
improved performance and space efficiency. Performance is further improved by sorting and 
indexing the file
The next step is then to quantify gene expression based on a gene annotation. This part of
the protocol is quite specific to comparisons between species, and is sensitive to errors. A single 
reference species is identified, in this protocol the mm10 annotation [Harrow et al., 2006][Meyer
et al., 2013], and the annotation file is downloaded in gff format. Constitutive exons- that is, 
exons which are always included in the final gene product- are then identified in this annotation 
using MISO, and all parts of the annotation which are not constitutive exons are discarded. 
Pairwise genome alignments of the chosen reference annotation to each query species are 
downloaded in turn in AXT format[Chiaromonte et al., 2002] [Kent et al., 2003] [Schwartz et al.,
2003]. All exons in the reference annotation which have complete orthologous regions in all 
query species genomes are then lifted to their respective orthologous position in each query 
species, while maintaining the gene IDs of the reference species. The resulting annotations are 
then converted from GFF format to GTF format using the gffread utility from the Cufflinks 
package [Trapnell et al., 2010]. This step is discussed in more detail in the next section as it is 
not covered in any other published protocols.
The annotations are then used to count the number of reads from the indexed alignment 
file which align to each exon, which is then used to calculate expression on a per-gene level. For 
comparison between species this pipeline uses a count-based method, rather than an FPKM-
based method for quantifying expression, as it is easier to integrate this into downstream 
expression analysis tools. The reason for this is threefold- firstly, many tools which compute 
differential expression (e.g. Cuffdiff) require that one annotation be given for all input alignment 
files, which will not function when comparing between species, with a different annotation for 
each species. Secondly, FPKM measurements take into account and report on the expression of 
genomic locations which are not included in the annotation, and these measurements will affect 
the values reported by the genes within the alignment. While this is desirable in most analysis 
cases, when comparing between species it makes less sense- as isoform discovery when 
comparing between species in this method is essentially impossible, and indeed the annotations 
are pared down to only those constitutive exons orthologously present in all queried species, 
differential expression analysis should focus on those exons and genes which can be measured in
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all samples. Finally, while single-sample FPKM programs such as Cufflinks can quantify 
alignments an annotation, since FPKM values are adjusted for feature length, it would become 
extremely difficult to adjust these values across species accounting for possible differences in 
feature length. Counts, on the other hand, are not adjusted by feature length- this means that 
counts cannot be used to compare expression of two different genes within a sample, such as
 when performing isoform-based analyses, but they are much more able to be used to compare 
expression of individual genes across multiple samples and species. Cufflinks, Cuffdiff, and 
other related tools may also be used as normal to compare expression within species using the 
data produced by the mapping portion of this protocol.
Once count data has been generated for each sample against its respective annotation 
using Rsubread [Liao et al., 2013], which returns the count information in a list. This list can 
then be read into edgeR [Robinson et al., 2009] which is able to perform a number of statistical 
tests upon the count data. Of primary importance, differential expression is computed for each 
gene between each sample, using a negative binomial distribution [McCarthy et al., 2012]. The 
list of differentially expressed genes may then be subset by magnitude and reported directly, as 
well as lend itself to further downstream analysis. In particular, this method will cover the use of 
SPIA [Tarca et al., 2008], GAGE [Luo et al., 2009] and Pathview [Luo et al., 2013], which are 
analysis packages from Bioconductor [Gentleman et al., 2004]. GAGE, which stands for 
“Generally Applicable Gene-set Enrichment”, will examine all differential expression between 
two samples, and determine which annotated cellular pathways are significantly different 
between the two samples, based on a given set of pathway annotations. This protocol utilizes 
pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) [Kanehisa et al., 2000], 
although others are supported by the software as well. This is done using a standard gene set 
enrichment, where DEGs are ranked by log fold change, and then based on ranks and numbers of
pathways, certain pathways are determined to be significant. SPIA performs similarly, but has the
added feature of also assessing the topology of the pathway- for example,  if one side of a 
comparison has many more genes involved in activation of a particular pathway and the other 
side has many more involved in repression, it will rate that pathway as more significant and 
interesting than were the DEGs randomly distributed through the pathway. However, this can 
also backfire if genes which are involved in both activation and repression are both upregulated 
in one sample, possibly reducing the likelihood of discovering pathways- for this reason, both 
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GAGE and SPIA are used. Once significantly different pathways have been determined, 
Pathview is given the gene names, pathway names, and expression levels, and it will query the 
KEGG servers for the pathway diagrams, annotating and coloring them in accordance with 
expression. Pathway-level expression analysis is the final goal of this protocol, enabling the 
researcher to view and explore the differences between two samples of different species, in terms
of one reference species' pathways, tying the difference in gene expression into the true 
biological differences, allowing for a much more human-readable set of results.
In addition to the above-mentioned pathway analysis charts, a number of scripts were 
written which leverage various other R packages to display various interesting aspects of the data
using heatmaps, Venn diagrams, and other charts.
Generation of cross-species genome annotations
The key to being able to compare RNAseq data between different species is the 
generation of a cross-species genome annotation. To do this, one species is selected as a 
'reference' species against which any other query species will be compared. In this protocol, the 
mouse genome and annotation are selected as the reference, because the mouse constitutes the in
vivo RNAseq data, while rat and human are in vitro- as the differences between in vitro and in 
vivo cells are of primary interest here, to minimize variation in the comparison which may be 
introduced by the new annotation. The goal is to ultimately compare all data from all relevant 
samples to one another in terms of genes and pathways in the reference species. The best way to 
do this is using orthologous genome regions- since many annotations may be variably complete, 
or have similarly named genes which have different functions, comparisons at a base pair level 
are used to determine which regions in the query species' genomes are to match up to each region
in the reference annotation.
One tool which is commonly used for the translation of genomic coordinates from one 
annotation version to another, or indeed one species to another, is the University of California 
Santa Cruz (UCSC)'s liftOver utility. However, the chain/net files used by liftOver are ill suited 
to comparisons between species, as small changes to the parameters can cause huge changes in 
the output when there is a large evolutionary distance between the two species. To adjust for this,
the UCSC conservation track, which is the best alignment between two genomes, is used instead.
This adds significant robustness to the comparison- not only are the comparison tracks partially 
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based on orthology as well as simple alignment score, but they are also symmetrical- that is, if a 
region in the mouse genome is converted to the rat genome using the conservation track, the 
resulting region in rat will convert back to the original region in the mouse. This is not always 
the case when using liftOver, due to the asymmetrical nature of dynamic masking in Blastz. The 
symmetry of the conservation track allows for a much more robust comparison between species.
Furthermore, the reference annotation is filtered such that only constitutive exons are 
included- that is, all exons which are always incorporated into the final gene product. As exact 
alternative splicings are far less likely to be conserved between species than entire genes, and 
because the additional small regions compared between genomes, conservation the cross-species 
annotations may have 'exons' for a gene on entirely separate chromosomes- as such, finding 
isoforms when comparing between species would be essentially meaningless, and is omitted 
from this protocol altogether.
Alternatives and Comparisons with Other Methods
To the best of the knowledge of the author, this is the first published protocol which 
provides a generally-applicable set of instructions for the comparison of RNA-seq data between 
different species. Previous papers have been published which have compared RNA-seq data 
between closely related species [Liu et al., 2011], and it is upon their methods sections that the 
novel parts of this protocol is partially based, while adapting many other parts of this protocol on
subsets of previously published protocols [Anders et al., 2013] and software which are already 
commonly used throughout the field. Another paper [Kristiansson et al., 2013] defines and 
implements a method for cross-species gene expression analysis as well, though this method 
does not provide a detailed step-by-step protocol for upstream preparation and downstream 
analyses. While the general idea is the same as the Liu paper- comparison of expression based on
orthology- the implementation is very different. There was a paper comparing human and mouse 
transcriptome data as well [Miller et al., 2010] which used similarity of gene networks to 
generate a consensus network that was used to compare expression between the species. For time
and complexity reasons, the Liu paper was selected as the basis for the cross-species analysis 
method. The goal of this protocol was to use off-the-shelf software when possible for the 
analysis of the data, while writing and publishing new code for ease of comparisons between 
species. There are often many options available for most steps in the protocol, which will work 
with similar input and output files, the user may alter some steps to use one of the many other 
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tools available, if they prefer to use Tophat rather than SHRiMP, or DEseq instead of edgeR, as 
drop-in replacements. The  Kristiansson method for cross-species comparison, while a viable 
alternative to the Liu method, is not a drop-in replacement and a separate protocol would need be
constructed to analyze data with it properly.
Confounding Effects
As this protocol seeks to compare RNA-seq data between different species using one 
annotation, differences in the procurement and treatment of the cells can introduce variations into
the data, as well as the relatedness of the species. The quantification of orthologous genes across 
species can at best only be an approximation based on alignment scores, and in distantly related 
species this may introduce confounding of the data. Furthermore, if the protocol is used to 
compare data from more than one study, differences in cell or data treatment between the studies 
may also introduce variation. It is advised that the user keeps track of all software versions and 
cell treatment protocols used, so that any differences may be used to determine whether 
downstream differences are the result of these factors or true biological expression differences. 
In the particular data shown, it is very difficult to differentiate differences in cells resulting from 
rat/mouse species divergence, and from in vitro/in vivo setting differences.
Materials
Hardware
The computing resources necessary for this protocol are heavy, particularly for the 
alignment of sequencing reads to the reference genome. While there are ways to reduce the 
memory footprint of the alignment if absolutely necessary, it is recommended to use a computer 
with at least 8 cores and 60GB of RAM, as well as at least 500GB of hard drive space. 
Additional resources will allow multiple samples to be run simultaneously, significantly speeding
the analysis.
Software
This protocol was constructed on and for a GNU/Linux operating system, and commands 
are given assuming that the user is using a POSIX-compliant operating system with access to a 
shell such as bash. While it is possible to run the protocol under Microsoft Windows, several 
additional steps would be necessary for the proper execution of various programs, which is 
outside the scope of this protocol. The author recommends one of the Debian or Red Hat distros 
for this protocol.
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The SHRiMP alignment software may be downloaded from 
http://compbio.cs.toronto.edu/shrimp/.
To work with the alignment files, SAMtools will be necessary for conversion, sorting, 
and indexing of the files. It may be installed from your distro's software repository or 
downloaded from http://samtools.sourceforge.net/.
Determination of constitutive exons leverages MISO, which can be downloaded from 
https://miso.readthedocs.org/en/fastmiso/index.html.
Various scripts and utilities for working with axt files, as well as various downstream 
analyses, where written by the author and may be downloaded from a git repo created for this 
protocol at https://github.com/ploverso.
The gffread utility, as well as other programs for downstream analysis, are part of the 
Cufflinks package and may be installed from your distro's software repository or downloaded 
from https://cole-trapnell-lab.github.io/cufflinks/.
The R statistical computing environment may be downloaded from 
http://cran.rstudio.com/.
Bioconductor and several of its packages (Rsubread, edgeR, gage, gageData, pathview, 
and Org.mm.eg.db) as well as all dependencies may be installed using the Bioconductor package 
installer.
The gplots R package may be installed using R's built-in package installer.
Following is the output of R's sessionInfo() command, which will show the versions of 
all packages used:
> sessionInfo()
R version 3.1.1 (2014-07-10)
Platform: x86_64-pc-linux-gnu (64-bit)
locale:
 [1] LC_CTYPE=en_US.utf8       LC_NUMERIC=C             
 [3] LC_TIME=en_US.utf8        LC_COLLATE=en_US.utf8    
 [5] LC_MONETARY=en_US.utf8    LC_MESSAGES=en_US.utf8   
 [7] LC_PAPER=en_US.utf8       LC_NAME=C                
 [9] LC_ADDRESS=C              LC_TELEPHONE=C           
[11] LC_MEASUREMENT=en_US.utf8 LC_IDENTIFICATION=C      
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attached base packages:
 [1] grid      splines   parallel  stats4    stats     graphics  
grDevices
 [8] utils     datasets  methods   base     
other attached packages:
 [1] org.Rn.eg.db_3.0.0   Rsubread_1.16.1      
BiocInstaller_1.16.4
 [4] VennDiagram_1.6.9    RColorBrewer_1.1-2   gplots_2.16.0    
 [7] gageData_2.3.1       gage_2.16.0          pathview_1.6.0   
[10] org.Hs.eg.db_3.0.0   KEGGgraph_1.24.0     graph_1.44.1      
[13] XML_3.98-1.1         edgeR_3.8.6          limma_3.22.7     
[16] org.Mm.eg.db_3.0.0   RSQLite_1.0.0        DBI_0.3.1        
[19] AnnotationDbi_1.28.2 GenomeInfoDb_1.2.4   IRanges_2.0.1    
[22] S4Vectors_0.4.0      Biobase_2.26.0       
BiocGenerics_0.12.1 
[25] biomaRt_2.22.0      
loaded via a namespace (and not attached):
 [1] Biostrings_2.34.1  bitops_1.0-6       caTools_1.17.1     
gdata_2.13.3      
 [5] gtools_3.4.2       httr_0.6.1         KEGGREST_1.6.4     
KernSmooth_2.23-14
 [9] png_0.1-7          RCurl_1.95-4.5     Rgraphviz_2.10.0   
stringr_0.6.2     
[13] tools_3.1.1        XVector_0.6.0      zlibbioc_1.12.0   
Input Data
RNAseq data from three different species were used: Rattus norvegicus, Mus musculus, 
and Homo sapiens. The samples for rat and human were prepared as described below, and then 
sent to the University of Rochester Genomics Research Center (URGRC),  who performed the 
sequencing and quality control on the reads. The cleaned sequencing reads were made available 
by and downloaded from URGRC to Research Computing at the Rochester Institute of 
Technology (RC) in FASTQ format. These data consist of two samples each of astrocytes, 
neurons, and oligodendrocyte progenitor cells (OPCs) from rats, all in vitro, and two samples of 
astrocytes and one sample of neurons from humans, also in vitro. The mouse samples were 
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prepared and sequenced as described in Zhang et al., 2014, and the input FASTQ files for in vivo 
astrocytes, neurons, and OPCs were downloaded from 
https://www.ebi.ac.uk/ena/data/view/SRP033200 to RC and extracted. All input files were based 
on output from Illumina sequencing machines- while other sequencers are supported by the 
alignment software, any conversions necessary are outside of the scope of this protocol.
Preparation of cells
Cells mentioned above were grown with 85% Dulbecco’s Modified Eagle’s Medium 
(DMEM) and 15% Fetal Bovine Serum (FBS). The cells were grown in 37°C  incubator with 5%
CO2 and a humidified atmosphere. Old medium was aspirated off  and replaced with new fresh 
pre-warmed media daily. The cells were subcultured on days 4 and 7. When sub culturing  the  
cells the media was removed and the cells were washed with Dulbeccos Phosphate-Buffered 
Saline (DPBS) without calcium and magnesium. The cells were then incubated with Stem Pro 
Accutase Cell Dissociation Reagent for twenty minutes while rocking the flasks back and forth 
every five minutes. The media that was removed initially was added back to the flask and the 
cells were moved to a pre-rinsed 15mL centrifuge tube and spun at 250 x g for five minutes. On 
day 10, RNA was isolated and sent to URGRC for sequencing.
Protocol
1. Preparation of reference genome
The reference genomes for human, rat, and mouse (hg38, rnor5, and mm10 respectively) 
were downloaded in compressed FASTA format from various sources- the rnor5 and mm10 
genomes with annotations were downloaded from Illumina's igenomes FTP server: 
ftp://igenome:G3nom3s4u@ussd-ftp.illumina.com/ while the hg38 genome FASTA was 
downloaded from the Sanger Institute, using version 20: 
ftp://ftp.sanger.ac.uk/pub/gencode/Gencode_human/release_20/GRCh38.genome.fa.gz. 
Furthermore, the comprehensive gene annotation for mm10 was downloaded in GFF format 
from GENCODE: http://www.gencodegenes.org/mouse_releases/3.html. Once the genome 
FASTA file was downloaded and extracted for each species, it was pre-processed with SHRiMP, 
which will greatly decrease the time required to align the RNAseq samples to that genome. The 
general command used to pre-process the genomes, run from the location of each genome.fa file,
is:
$ ~/SHRiMP_2_2_3/bin/gmapper-ls -S <assemblyName> -N 8 genome.fa
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This will index the genome and save the indexes and projections of the genome to file, which are
then loaded for each sample to align against. If this pre-processing step is not done, then it will
be performed prior to mapping for each sample, causing the alignment step per sample to 
take many hours longer. The index files will be several times larger than the original genome.fa
files, and should be placed in a location convenient to the RNAseq samples.
2. Alignment of RNAseq reads to indexed genome
Each sample should then be aligned to its respective genome, specified with the assembly
name given when indexing. This step is the most computationally intensive, and should be 
performed on a computer with at least 60GB of RAM. This step can be parallelized easily, and 
allotting more CPU cores to the alignment will allow it to run significantly faster. The author 
suggests writing a simple bash script to run the alignments, to reduce the amount of oversight 
necessary for large numbers of samples. The general command used to align the rat and human 
data is:
$ ~/SHRiMP_2_2_3/bin/gmapper-ls -Q --qv-offset 33 -L 
./<indexLocation>/<assemblyName> -N 8 --all-contigs $infile > 
$outfile
This will output the alignment to the specified output file in SAM format. This command is only 
valid for the rat and human data, which is single-ended RNAseq data. The mouse data is paired-
end data, with each sample name suffixed with a _1 or _2 in the FASTQ filename. The command
used for the mouse data was, generally:
$ ~/SHRiMP_2_2_3/bin/gmapper-ls -Q --qv-offset 33 -L 
./<indexLocation>/mm10 -N 8 --all-contigs -p opp-in -1 $infile1 
-2 $infile2 > $outfile
The -p option specifies how SHRiMP will attempt to align the paired-end data. Mapping 
statistics for all samples is shown in Table 1.
3. Conversion, sorting, and indexing of SAM files
The SAM output of SHRiMP is a plain-text file. While somewhat human-readable, it is 
uncompressed and each SAM file may be many tens of GB. The filesize will slow access to the 
file when it is accessed for analysis, and inflate space required on a hard drive. To solve these 
problems, the SAM files are converted to the compressed binary BAM format, then sorted and 
indexed. The general commands used for this are as follows:
$ samtools view -bS $inSAM > $tempBAM
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$ samtools sort $tempBAM $outPrefix && rm $tempBAM
$ samtools index $outBAM 
BAM files which are sorted and indexed have greatly enhanced access speeds, which will speed 
up downstream analysis. Additionally, BAM files tend to be only a small fraction the size of the 
SAM files whence they came, freeing up disk space and reducing RAM requirements for 
downstream analysis programs which load the entire BAM file into memory.
Alternative protocol entry point
If the user decided to use a different alignment method than SHRiMP, such as Tophat or 
GSNAP, then they should enter the protocol at this point with their sorted, indexed BAM files.
4. Generation of cross-species annotations
Starting with the GFF file downloaded from GENCODE in a previous step, the 
constitutive exons must be identified. This is done with the exon_utils program, part of MISO. 
The command:
$ exon_utils --get-const-exons mm10.gff --min-exon-size 100 
--output-dir exons/
This will extract all constitutive exons (that is, all exons always incorporated into the 
final gene product) which are greater than 100bp into a GFF file in a specified folder. This file is 
then broken down into individual chromosomes using a perl script from the github repo specified
above, gffToChrs.pl.
$ perl gffToChrs.pl mm10.const_exons.gff ./gffChrs/
Next, the axt files must be downloaded, one axt file per chromosome. The wget utility 
may be helpful in doing so. The axt files are provided for many species by UCSC, for example: 
http://hgdownload.cse.ucsc.edu/goldenPath/mm10/vsRn5/axtNet/. Then, the axtLift.pl script is 
used to convert each chromosome of the reference annotation to the coordinates of the query 
annotation. Exons which do not match 100% are discarded- that is, if the exon hangs off one end 
or the other of the aligned region. Alignments with gaps are supported. However, before this can 
be run, the annotation must be filtered. Downstream analysis programs will not work if the gene 
names in the annotations differ between species. So, prior to translating the mm10 genomic 
coordinates to rnor5 or hg38, the entire mm10 annotation is first run against each genome 
conservation track, and the mm10 annotation lines are output as-is into a new single annotation 
file for each species, which can then be combined. A perl script has been written for this purpose.
To run, for example:
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$ perl axtCompare.pl ./gffChrs/chr1.gff 
./mm10TOrn5/chr1.mm10.rn5.net.axt ./rn5.gff
$ perl axtCompare.pl ./gffChrs/chr1.gff 
./mm10TOhg38/chr1.mm10.hg38.net.axt ./hg38.gff
Note that the above command is an example, and must be run for each chromosome for 
each species. The script only supports a single input GFF and AXT file at a time, so a bash script 
may be useful to run all chromosomes for the reference species. If this step needs to be redone 
for any reason, the output files should be deleted or renamed prior to beginning a new run, as the 
script will append rather than overwriting files.
The purpose of the above script is to enable the comparison of the exons which map to 
rnor5 and hg38, and subset the final annotations for all three species- mm10, hg38, and rnor5- 
into only the genes which perfectly remap to both hg38 and rnor5. It tests only that the exon will 
remap correctly, but does not actually change the annotation line. Combining the files and 
finding the lines in common can be done trivially with R. Using the files mentioned above:
$ R
> rnData <- read.delim("rn5.gff", header=F)
> hgData <- read.delim("hg38.gff", header=F)
> finalData <- merge(rnData, hgData)
> write.table(finalData, file="mm10_final.gff", row.names=F, 
col.names=F, quote=F, sep="\t")
Once this has been done, this new GFF file must again be split into chromosomes, similar
to above:
$ perl gffToChrs.pl mm10_final.gff ./finalChrs/
Then, the individual chromosome files are mapped to the new genomes. The axtLift.pl 
script will do this. To run this script, for example:
$ perl axtLift.pl ./finalChrs/chr1.gff 
./mm10TOrn5/chr1.mm10.rn5.net.axt ./rn5/
$ perl axtLift.pl ./finalChrs/chr1.gff 
./mm10TOhg38/chr1.mm10.hg38.net.axt ./hg38/
It should be noted that the output folder must be created prior to running the script. 
Furthermore, any files in the folders should be deleted if this step needs to be rerun, as the script 
will append rather than overwriting files. The script only supports a single input GFF and AXT 
file, so a bash script may be useful to run all chromosomes for the reference species. It is not 
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recommended to run the chromosomes in parallel, as each input chromosome may map to any of 
the output chromosome files.
Once this completes, the GFF files should be sorted and combined into a single 
annotation file. This is again easy to do with R. For example with hg38:
$ R
> final <- data.frame(matrix(nrow=0, ncol=9))
> for(gffFl in dir("hg38")){
+ gffData <- read.table(paste0("./hg38/", gffFl), header=F, 
sep="\t", as.is=T)
+ gffData <- gffData[order(gffData[,4]),]
+ final <- rbind(final, gffData)
+ }
> write.table(final, file="hg38_final.gff", row.names=F, 
col.names=F, quote=F, sep="\t")
Important: The final annotation for each species MUST be in the same chromosomal 
order as the genome.fa file for that species, otherwise the final GFF file will be sorted improperly
and many gene quantification tools will fail to work. Additionally, chromosomes must be in the 
same format as in genome.fa for that species (e.g. “chr10” vs “10”).
Finally, the GFF files should be converted to GTF format. GTF is essentially a simplified,
more specific form of the GFF format. The Cufflinks package comes with a utility for 
performing this conversion, gffread.
$ gffread hg38_final.gff -T -o hg38.gtf
$ gffread mm10_final.gff -T -o mm10.gtf
$ gffread rn5_final.gff -T -o rnor5.gtf
These GTF files are then used together with the BAM files generated previous to quantify
expression at a per-gene level.
5. Counting of gene features
The next step is to quantify the expression for each sample, which here is done using the 
Bioconductor package Rsubread. The package will take the BAM files and the GTF annotation, 
as well as some other parameters describing the data, and produce a count table of each gene ID. 
As the count data is returned as a variable to the R environment rather than written to a file, and 
as Rsubread will output information such as the number and percent of successfully counted 
reads, it may be advisable to use a script for counting and to redirect terminal output to a file for 
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saving. The R commands used for   the counting of all data in this experiment, as well as for 
saving the R environment with all count data for later analysis, are as follows:
$ R
> library(Rsubread)
> allSpecies <- c("rnor5", "hg38", "mm10")
> origDir <- getwd()
> countedData <- list()
> for(species in allSpecies){
+ cells <- c("ast1", "ast2", "neu1", "neu2", "opc1", "opc2")
+ setwd(species)
+ annotLoc <- paste0("../annotations/", species, ".gtf")
+ if(species == "hg38"){
+ cells <- c("ast1", "ast2", "neu1")
+ }
+ for(cell in cells){
+ cellData <- paste0(cell, ".bam")
+ isPair <- F
+ if(species == "mm10"){
+ isPair <- T
+ }
+ thisID <- paste0(species, cell)
+ sampleCount <- featureCounts(cellData, annot.ext=annotLoc, 
isGTFAnnotationFile=T, GTF.featureType="exon", 
GTF.attrType="gene_id", useMetaFeatures=TRUE, 
allowMultiOverlap=FALSE, isPairedEnd=isPair, nthreads=4L)
+ countedData[[thisID]] <- sampleCount
+ }
+ setwd(origDir)
+ }
> save(countedData, file="counts.Rdata")
This last command will save all of the data, from all of the samples, to a file which can be
re-loaded by R at any time. This is useful when analysis may be done on a computer that the 
researcher may not have access to all the time, or when further analysis may be desired at a later 
time. Unless saved, the data is deleted when the R environment is closed.
The data is then prepared for loading into edgeR. The input format for edgeR is a matrix 
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with the counts for each sample for each gene ID- it may simplify analyses to extract these to 
their own text file using R:
> load("counts.Rdata")
> counts <-countedData[[1]][[1]]
> counts <- data.frame(counts[order(rownames(counts)),])
> for(samp in names(countedData)[2:length(names(countedData))]){
+ newData <- countedData[[samp]][[1]]
+ newData <- data.frame(newData[rownames(newData) %in% 
rownames(counts),])
+ rows <- rownames(counts)[rownames(counts) %in% 
rownames(newData)]
+ counts <- data.frame(counts[rownames(counts) %in% 
rownames(newData),])
+ rownames(counts) <- rows
+ newData <- newData[order(names(newData))]
+ counts <- cbind(counts, newData)
+ }
> colnames(counts) <- names(countedData)
> write.table(counts, file="counts.txt", quote=F, sep="\t")
The above commands do some additional sorting and filtering to ensure that all genes for 
all samples are in the correct order, and there are no gene IDs which do not exist for all samples.
6. Differential expression analysis
Once the files with the counts have been prepared, they can be analyzed with edgeR for 
differential expression. EdgeR was chosen in particular for the differential expression analysis 
thanks to several useful features. Firstly, it supports input in the form of a single matrix of counts
with gene IDs as the names for each row, allowing easy integration of the counted data from the 
previous step. Secondly, it has superb support for complex comparisons and experimental 
design- it is trivial to compare individual samples, or specify groups for comparison, or even to 
make two comparisons, and compare the results of that comparison against one another, allowing
for essentially any dimension of analysis desired.
To load the count data into edgeR and then build the labeled experiment design, estimate 
the count dispersions, and build a fitted model, the following commands were used which are 
defined in an R script in the github repo mentioned above. Full code for the downstream analysis
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can be found in the appendices- due to the length of the code, complete commands have been 
omitted from the main document, and while all steps will be explained, only some particular 
commands will be shown.
The generated experimental design matrix(specifying which samples/replicates in the 
'counts.txt' file to include under which labels) appears as follows:
> design
   hgast hgneu mmast mmneu mmopc rnast rnneu rnopc
1      0     0     0     0     0     1     0     0
2      0     0     0     0     0     1     0     0
3      0     0     0     0     0     0     1     0
4      0     0     0     0     0     0     1     0
5      0     0     0     0     0     0     0     1
6      0     0     0     0     0     0     0     1
7      0     0     0     0     1     0     0     0
8      0     0     0     0     1     0     0     0
9      0     0     0     1     0     0     0     0
10     0     0     0     1     0     0     0     0
11     0     0     1     0     0     0     0     0
12     0     0     1     0     0     0     0     0
13     1     0     0     0     0     0     0     0
14     1     0     0     0     0     0     0     0
15     0     1     0     0     0     0     0     0
attr(,"assign")
[1] 1 1 1 1 1 1 1 1
attr(,"contrasts")
attr(,"contrasts")$Group
[1] "contr.treatment
While not strictly necessary, a design matrix is exceptionally useful as it then allows 
comparisons to be built with the makeContrasts() function in edgeR, specifying groups to 
compare by their group name, rather than manually entering number values representing which 
columns to include at certain weights. The following command was used to define 48 
comparisons which would be made among the data, each of which would have its own 
differential gene expression analysis.
my.contrasts <- makeContrasts(
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rn.astVSrest = rnast - (rnneu + rnopc)/2,
rn.neuVSrest = rnneu - (rnast + rnopc)/2,
rn.opcVSrest = rnopc - (rnneu + rnast)/2,
mm.astVSrest = mmast - (mmneu + mmopc)/2,
mm.neuVSrest = mmneu - (mmast + mmopc)/2,
mm.opcVSrest = mmopc - (mmneu + mmast)/2,
ast.vtVSvv = (hgast + rnast)/2 - mmast,
neu.vtVSvv = (hgneu + rnneu)/2 - mmneu,
opc.vtVSvv = rnopc - mmopc,
all.vtVSvv = (hgast + hgneu + rnast + rnneu + rnopc)/5 - 
(mmast + mmneu + mmopc)/3,
all.rnVSmm = (rnast + rnneu + rnopc)/3 - (mmast + mmneu + 
mmopc)/3,
ast.rnVShg = rnast - hgast,
ast.rnVSmm = rnast - mmast,
ast.hgVSmm = hgast - mmast,
neu.rnVShg = rnneu - hgneu,
neu.rnVSmm = rnneu - mmneu,
neu.hgVSmm = hgneu - mmneu,
rn.astVSneu = rnast - rnneu,
mm.astVSneu = mmast - mmneu,
hg.astVSneu = hgast - hgneu,
rn.astVSopc = rnast - rnopc,
mm.astVSopc = mmast - mmopc,
rn.neuVSopc = rnneu - rnopc,
mm.neuVSopc = mmneu - mmopc,
vt.astVSneu = (rnast + hgast)/2 - (rnneu + hgneu)/2,
vv.astVSneu = mmast - mmneu,
vt.astVSopc = (rnast + hgast)/2 - rnopc,
vv.astVSopc = mmast - mmopc,
vt.neuVSopc = (rnneu + hgneu)/2 - rnopc,
vv.neuVSopc = mmneu - mmopc,
astneu.vtVSvv = ((rnast - rnneu) + (hgast - hgneu))/2 - 
(mmast - mmneu),
astopc.vtVSvv = ((rnast + hgast)/2 - rnopc) - (mmast - 
mmopc),
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neuopc.vtVSvv = ((rnneu + hgneu)/2 - rnopc) - (mmneu - 
mmopc),
astRest.vtVSvv = ((rnast + hgast)/2 - (rnneu + hgneu + 
rnopc)/3) - (mmast - (mmneu + mmopc)/2),
neuRest.vtVSvv = ((rnneu + hgneu)/2 - (rnast + hgast + 
rnopc)/3) - (mmneu - (mmast + mmopc)/2),
opcRest.vtVSvv = (rnopc - (rnneu + hgneu + rnast + hgast)/4)
- (mmopc - (mmneu + mmast)/2),
astneu.rnVSvv = (rnast - rnneu) - (mmast - mmneu),
astopc.rnVSvv = (rnast - rnopc) - (mmast - mmopc),
neuopc.rnVSvv = (rnneu - rnopc) - (mmneu - mmopc),
astRest.rnVSvv = (rnast - (rnneu + rnopc)/2) - (mmast - 
(mmneu + mmopc)/2),
neuRest.rnVSvv = (rnneu  - (rnast + rnopc)/2) - (mmneu - 
(mmast + mmopc)/2),
opcRest.rnVSvv = (rnopc - (rnneu + rnast)/2) - (mmopc - 
(mmneu + mmast)/2),
vt.astVSrest = (rnast + hgast)/2 - (rnneu + hgneu + 
rnopc)/3,
vt.neuVSrest = (rnneu + hgneu)/2 - (rnast + hgast + 
rnopc)/3,
vt.opcVSrest = rnopc - (rnneu + hgneu + rnast + hgast)/4,
all.astVSneu = (rnast + mmast + hgast)/3 - (rnneu + mmneu +
hgneu)/3,
all.astVSrest = (rnast + mmast + hgast)/3 - (rnneu + mmneu 
+ hgneu + rnopc + mmopc)/5,
all.neuVSrest = (rnneu + mmneu + hgneu)/3 - (rnast + mmast 
+ hgast + rnopc + mmopc)/5,
all.opcVSrest = (rnopc + mmopc)/2 - (rnneu + mmneu + hgneu 
+ rnast + mmast + hgast)/6,
levels=design)
The above comparisons allow for the determination of differentially expressed genes 
between in vitro and in vivo cells, both generally across all cell types as well as on a per-cell-type
basis. Comparisons of cellular differences between the individual species as well as comparisons 
between the cell types are also defined. Not all of the above comparisons wound up having their 
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data used for the final reporting of results- however, the presence of many of these comparisons 
allowed for additional error checking of the data, and additionally, as analyses were done, certain
comparisons which had not been of interest before came to be of interest- it can be useful to have
all of the data pre-processed and ready to go if it should be decided that any subset of it may be 
needed, rather than adding onto already existing data structures after the fact.
The next step is to use glmLRT() and the fitted model to find all differentially expressed 
genes, which is done by looping through the data frame of comparisons. The result of each 
comparison is saved in a list for later access.
The table of fold changes and FDR-corrected p-values is then used with GAGE and SPIA
to perform KEGG pathway enrichment for that comparison. Note: GAGE and SPIA will perform
its enrichment analysis on only the fold change values, and cannot easily be made to account for 
the sample sizes for that comparison in edgeR. This causes the q-value outputs from GAGE to be
falsely inflated. To account for this, the edgeR differential expression table is filtered to only 
include genes with a p-value of <0.05, and a FDR of <0.01. Only these significantly expressed 
genes with a low FDR are used in the calculation of enriched pathways. All KEGG pathway IDs 
found with a p-value <0.05 are then returned and also saved to a list for further use.
7. Visualization of data
Using the gene expression and pathway data contained in the lists described above, the 
data is then graphed and visualized. Firstly, Pathview was used to visualize differentially 
enriched pathways, downloading the pathway map from KEGG, and then color-coding each gene
with the fold-change differences. The pathways enriched in individual cell types when 
comparing in vitro to in vivo were combined, and the expression data for all three cell types was 
visualized on single graphs per pathway, splitting the coloring of each gene into thirds. Pathways
showing the difference between astrocytes and neurons were similarly combined, splitting each 
gene marker into thirds by species. The pathways differentially expressed in general between in 
vitro/in vivo were visualized on their own set of pathways. The R code for these comparisons is 
included in the github repo mentioned above.
The general gene expression profiles were then visualized using R scripts written for the 
purpose. The gene expression values for each gene were quantified from the gene read counts 
with log2(counts per million(CPM) + 1). Several charts were then generated from this. Firstly, a 
heatmap showing the 200 genes with the highest expression in any sample were shown, sorted by
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similarity of expression across all samples. The log2(CPM + 1) table was then regenerated, using
mean counts per species cell type, as divided in the experimental design above. A heatmap was 
drawn with the top 200 expressed genes of any cell type, sorted by similarity of expression 
across all cell types. Finally, a heatmap was drawn with the top 25 expressed genes for each of 
the eight cell types in turn, sorted top to bottom by expression level in that cell type. These 
heatmaps illustrate the similarities and differences among the cell types examined, allowing for 
easy visual identification of potential problems in the data that may not have been clear earlier in
the  protocol, such as if two replicates of the same cell type present extremely different 
expression profiles. These heatmaps were drawn using the “gplots” R package. In the heatmaps, 
the gene symbol names are displayed next to each row. The cross-species annotation uses 
exclusively Ensembl gene IDs- the biomaRt Bioconductor package was used to translate these 
IDs to gene symbols.
Furthermore, Venn diagrams were generated using the “VennDiagram” R package to 
visualize which genes among lists of DEGs are in common or different between various 
comparisons, which has the potential to grant further biological insight. Tables of the numbers of 
DEGs were also produced.
8. Pathway analysis and visualization
While lists of differentially expressed genes are a detailed and robust way to represent 
differences in expression between two samples, they are not a very friendly format for humans to
understand. A table of thousands of gene ID tags, each with individual expression values, is not 
easily read and visually extrapolated to biological significance. To this end, GAGE and SPIA are 
used to analyze the previously generated gene lists and determine the differentially expressed 
pathways. Unfortunately, neither of these software packages has the capacity to properly deal 
with asymmetrical input samples in the way that this experiment requires- for this reason, the 
FDR values reported by either of these software packages will not be accurate. To deal with this, 
the FDR values for individual genes as provided by edgeR are used instead, and the pathway 
output of SPIA and GAGE are instead filtered by p-value instead of q-value. When these 
pathways are passed into Pathview for visualization, only the genes with a q-value less than 0.05 
are provided, so in the final pathway charts only significant genes are used. It should be noted 
that the SPIA package provided by Bioconductor has many of its significance values hardcoded, 
and also lacks handling for some data aberrations such as NA values in R. The source code for 
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this package was downloaded and modified to suit the purposes of this experiment. As SPIA is 
licensed under the GPL, this modified source code must be made available to the general public. 
It has been hosted in the github repo mentioned above. Scripts were written which would 
perform both GAGE and SPIA pathway enrichments on all of the comparisons mentioned above,
and save the results. As both of these packages take Entrez IDs as input, and the genes are listed 
by Ensembl ID, a script was written to leverage Bioconductor's “org.Mm.eg.db” package to 
convert the IDs.
Once lists of significantly enriched pathways have been generated, the KEGG IDs of 
enriched pathways for each comparison is fed into Pathview, which will query each pathway ID 
against the KEGG database and download the PNG and XML files for that pathway map. It will 
also take the list of DEGs and log fold change values for that comparison, and color-code genes 
on the pathway map to illustrate which parts of that pathway are differently expressed, and in 
what direction. These images are then saved to a folder for manual examination. Furthermore, as 
each list of differentially expressed pathways is produced, tables of all pathway names and 
significance values are saved for future reporting.
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Section 4
Results: Comparison of transcriptional profiling between in vivo and in vitro settings in
mammalian neural cells
Overview of results
The results presented herein are separated into several sections. Firstly, statistics and 
percentages collected during the alignment and quantification of RNA-seq samples are presented
in tabular form. SHRiMP reports in detail on mapping statistics for each sample, which can be 
important to look over before proceeding with analysis- low percentages of aligned reads, or 
samples with large outliers from the other samples, may indicate a problem with the quality 
control of the data. Counts and percentages are then shown for the quantification of the aligned 
samples against each of the two annotations used for each species.
The next section shows the gene quantification and pathway analysis results of 
comparisons between cell types within species for all in vitro samples using the literature 
annotation for that species. Heatmaps of differentially expressed genes (DEGs) are presented for 
each comparison, and then selected pathway maps are shown with DEGs colored, to illustrate 
differences in cellular activity between cell types. These pathways and DEGs are compared with 
the literature to demonstrate that expected results have been attained, and verify the ability of the
experiment to provide consistent results. Then, the same comparisons are made using the cross-
species annotation generated for each species, and the results of these are then compared. By 
showing that the analysis using the cross-species annotation yields similar results to the true 
annotation for each species, the utility of the cross-species annotation can be confirmed, lending 
additional credence to the comparison of in vitro data against its in vivo counterparts.
Once cell-type comparisons within species in vitro have been completed, the next step is 
to compare the in vitro data against published in vivo data of the same cell types. These 
comparisons allow the illustration of which specific biological processes are different in vitro 
compared to in vivo. Papers are often published where cells are treated and analyzed in vitro, and
results are frequently extrapolated to include in vivo cells without the use of those in vivo cells 
for various reasons. The results shown here identify areas of certain pathways which are 
significantly different between in vitro and in vivo cells, and may provide a guideline for future 
experiments as to whether in vivo cells should be sought for use, if genes or pathways shown to 
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be differently expressed in that  are important in the context of the experiment being undertaken.
A) Data processing: Genome alignment
The RNAseq reads for the rat, human, and mouse samples were aligned to the rnor5, 
hg38, and mm10 genome assemblies respectively using SHRiMP. The output was saved in SAM 
files for each sample, and then converted to BAM format to be sorted and indexed. The mapping 
statistics for all input files is shown in Table 1. Very low mapping statistics for a sample can 
indicate a problem with the input data, or with the commands used to align it. The mapping 
statistics shown here are fairly consistent, with all samples mapping greater than 75% of their 
reads, and all mapping more than 70% at a quality greater than ten.
A:
R. norvegicus Astrocyte 
replicate 1
Neuron replicate 1 Neuron replicate 2 OPC replicate 1 OPC 
replicate 2
Reads matched 37,499,371    
(92.2925%) 
70,917,604    
(90.7163%)
44,661,252    
(92.6240%)
18,373,876    
(89.9179%)
33,709,300
(87.7766%
)
...with QV >= 10 31,977,341    
(78.7018%) 
64,870,497    
(82.9810%)
39,651,012    
(82.2332%)
16,197,222    
(79.2658%)
28,766,309
(74.9054%
)
Reads dropped 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Total matches 102,616,135 144,690,005 112,161,735 44,632,937 96,670,217
Avg hits/ Matched read 2.74 2.04 2.51 2.43 2.87
Duplicate hits pruned 3,862,843 4,518,414 4,189,579 1,566,548 3,948,009
B:
H. sapiens Astrocyte replicate 1 Astrocyte replicate 2 Neuron replicate 2
Reads matched 42,671,125    (91.2301%) 43,979,971    (90.3046%) 37,383,296    
(78.6239%)
...with QV >= 10 38,721,254    (82.7854%) 39,925,948    (81.9804%) 32,386,717    
(68.1152%)
Reads dropped 0 (0%) 0 (0%) 0 (0%)
Total matches 124,458,271 127,679,763 144,344,276
Avg hits/ Matched read 2.92 2.9 3.86
Duplicate hits pruned 3,867,809 3,939,406 5,795,400
C:
M. musculus Astrocyte Astrocyte Neuron Neuron OPC OPC 
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replicate 1 replicate 2 replicate 1 replicate 2 replicate 1 replicate 2
Pairs matched 24,482,027    
(82.6456%)
27,236,030    
(85.0626%)
32,405,280    
(85.5175%)
26,691,409    
(78.6388%)
26,763,308    
(83.0340%)
26,637,899    
(81.9936%)
...with QV >= 10 23,584,181    
(79.6147%)
26,210,006    
(81.8581%)
30,734,414    
(81.1081%)
25,195,971    
(74.2329%)
24,776,706    
(76.8705%)
24,777,771    
(76.2680%)
Pairs Dropped 542,030    
(1.8298%)
355,132    
(1.1091%)
724,441    
(1.9118%)
2,380,366    
(7.0131%)
549,008    
(1.7033%)
632,688    
(1.9475%)
Total paired matches 42,835,593 47,459,160 70,617,958 55,945,227 55,564,357 69,030,232
Avg hits/ Pair Matched 1.75 1.74 2.18 2.10 2.08 2.59
Duplicate Paired 
Matches Pruned
3,041,374 3,509,155 5,597,592 3,962,805 4,003,436 4,983,493
Additional Reads 
Matched Unpaired
12,659,160    
(21.3672%)
12,592,596    
(19.6644%)
19,994,811    
(26.3832%)
15,774,322    
(23.2373%)
15,850,311    
(24.5880%)
20,709,809    
(31.8732%)
...with QV >= 10 3,893,594    
(6.5719%)
3,670,766    
(5.7322%)
3,998,582    
(5.2761%)
3,783,291    
(5.5732%)
3,911,560    
(6.0679%)
4,155,722    
(6.3958%)
Total Unpaired Matches 79,200,816 85,797,139 141,283,381 108,106,066 106,012,971 141,510,462
Avg Matches/
Unpaired Matched Read
6.26 6.81 7.07 6.85 6.69 6.83
Duplicate Unpaired 
Matches Pruned
2,619,023 3,078,362 5,559,007 4,016,369 3,938,977 4,852,651
Table 4-1: SHRiMP alignment statistics of each input file. Statistics are shown for (A) R. 
norvegicus cells, single-end data from in vitro cells; (B) H. sapiens cells, single-end data from in 
vitro cells, and (C) M. musculus cells, paired-end data from in vivo cells.
B) Data processing: Generation of cross-species annotations
The GFF file downloaded from GENCODE contained the current annotation of the 
mm10 genome assembly. The first step towards generating cross-species alignments is the 
identification of constitutive exons. Using the exon_utils program, a total of 79275 constitutive 
exons was identified in the original annotation out of a pool of 651,678 known exons, 12.16% of 
its original size. When the AXT files were used to find orthologous regions, it was found that 
68109 (85.91%) exons mapped perfectly to the rnor5 assembly, and 59556 (75.13%) mapped 
perfectly to the hg38 assembly. Taking the union of the two sets of mapped genes yielded a set of
56710 (71.54%) constitutive exons which mapped perfectly to both other species, and it is these 
which formed the final assembly annotations for all three species.
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Once annotations had been generated for all three assemblies, Rsubread was used to 
count the number of aligned reads which matched up to features in the annotation. The counts of 
matching reads are shown in Table 2. The percentages of reads which align properly with the 
annotations is quite low- but this is to be expected, as the original annotation was pared down to 
a small fraction of its original size. To double-check the quality of the data, the BAM files were 
also counted against the unaltered literature annotations for each species, and the percentage of 
counts aligned to features using the true annotation is shown in Table 3.
R. norvegicus Astrocyte 
replicate 1
Astrocyte 
replicate 2
Neuron 
replicate 1
Neuron 
replicate 2
OPC replicate 
1
OPC replicate 
2
Total reads 75497691 102616135 144690005 112161735 44632937 96670217
Successfully 
assigned reads
11481267 
(15.2%)
13525196 
(13.2%)
20170805 
(13.9%)
15920999 
(14.2%)
5968080 
(13.4%)
12086305 
(12.5%)
H. sapiens Astrocyte replicate 1 Astrocyte replicate 2 Neuron replicate 1
Total reads 124458271 127679763 144344276
Successfully assigned reads 11207432 (9.0%) 11483640 (9.0%) 13918960 (9.6%)
M. musculus Astrocyte 
replicate 1
Astrocyte 
replicate 2
Neuron 
replicate 1
Neuron 
replicate 2
OPC replicate 1 OPC replicate 2
Total fragments 79200816 85797139 141283381 108106066 106012971 141510462
Successfully 
assigned fragments
11988435 
(15.1%)
12779470 
(14.9%)
18058574 
(12.8%)
17431605 
(16.1%)
18217286 
(17.2%)
20874926 
(14.8%)
Table 4-2: The number of input fragments which were successfully matched against the 
generated cross-species annotations are shown here. The low percentages are to be expected, as 
the annotation was cut down to just over 12% of its original size.
R. norvegicus:
rnor5
Astrocyte 
replicate 1
Astrocyte 
replicate 2
Neuron 
replicate 1
Neuron 
replicate 2
OPC replicate 
1
OPC replicate 
2
Total reads 193401932 102616135 144690005 112161735 44632937 96670217
Successfully 
assigned reads
102861667 
(53.2%)
50267809 
(49.0%)
75601751 
(52.3%)
55520161 
(49.5%)
22265917 
(49.9%)
45077708 
(46.6%)
H. sapiens:hg38 Astrocyte replicate 1 Astrocyte replicate 2 Neuron replicate 1
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Total reads 124458271 127679763 144344276
Successfully assigned reads 84417123 (67.8%) 86422474 (67.7%) 98457922 (68.2%)
M. musculus: mm10 Astrocyte 
replicate 1
Astrocyte 
replicate 2
Neuron 
replicate 1
Neuron 
replicate 2
OPC replicate
1
OPC replicate
2
Total fragments 79200816 85797139 141283381 108106066 106012971 141510462
Successfully assigned
fragments
39834149 
(50.3%)
42129607 
(49.1%)
54378124 
(38.5%)
50623908 
(46.8%)
50289978 
(47.4%)
56724880 
(40.1%)
Table 4-3: The number of input fragments which were successfully matched against the 
published annotation for that genome assembly are shown here.
The data shown prove to be quite consistent. Almost all of the SHRiMP alignments report
75-80% of reads matched with a quality value greater than or equal to ten, with the lowest still at 
68%. The percentage of these reads which then properly map to the cross-species annotation is 
fairly low- between 9 and 16% for most samples. However, the percentages for the rat and 
mouse samples are quite close, indicating that the quality of the annotation is not significantly 
worse after it has been translated across species. The percentages for the human data are lower, 
but this is to be expected as humans are evolutionarily much farther from mice than rats are. 
When using the corrected annotations, percentages of reads which align to known features 
increases significantly, and are fairly consistent within species as well. This again indicates that 
the data collected are fairly consistent and not the result of poor quality control.
C) In vitro/ in vitro comparison: Differences in expression between in vitro rat neural cells
Once features were counted, expression was quantified among the samples involved. 
These were visualized first by creating a heatmap of the 200 top expressed genes in the 
experiment, grouped both by sample and by overall group, shown in figure 4-1. Furthermore, 
several classic cell-type-specific marker genes were selected, and a heatmap showing the 
differences in expression of these genes in different cell types was generated, shown in figure 4-
2. The marker genes shown are based on a previously published list including these genes as well
as others for other cell types [Zhang et al., 2014][Lovatt et al., 2007]. As can be seen, the marker 
genes provide excellent stratification of expression by cell type, which verifies the identity of 
these cells against known expression patterns. These expression patterns help indicate that there 
was no contamination between the samples and that they at least generally tend to follow the 
same gene expression as previously published results.
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Next, comparisons were made between the different cell types in R. norvegicus, using the
literature genome annotation by grouping the individual samples by cell type. Differences were 
quantified both between individual cell types, and between each cell type and all others 
combined. Figure 4-3 shows the numbers of differentially expressed genes (DEGs) in common 
between the pairwise comparisons made, and figure 4-4 shows those DEGs in common between 
the comparisons made of each cell against all other cell types. The data presented in both figures 
is as expected. In figure 4-3, and genes highly expressed or lowly expressed in astrocytes against 
the other cell types would be expected to be in common between the Ast/OPC and Ast/Neu 
groups, and the same is true for the expression of OPCs in the Ast/OPC and Neu/OPC groups. 
Any DEGs shared between Ast/Neu and Neu/OPC are genes where expression is significantly 
increased in astrocytes as well as decreased in OPCs, or vice versa. For this reason there should 
be no genes shared by Neu/OPC and Ast/Neu which are not also in Ast/OPC, and this is indeed 
the case.
In figure 4-4, there should be a minimum of genes shared between any of the groups, as 
for genes to be significantly increased in expression in two groups, it means the third must have 
such decreased expression as to show as significant even when combined with the third cell type.
This also means that necessarily, all genes marked as upregulated in two cell types must 
necessarily also be marked as downregulated in the third cell type. Examinations of the lists of 
genes making up the figure has shown this to indeed be the case (data not shown).
37
A B)
Figure 4-1: The 200 genes with the highest expression in the experiment, grouped by similarity 
of expression across rows. Expression by cell type (A) and by individual sample (B) is shown.
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Figure 4-2: A heatmap comparing the expression of various cell-type marker genes. The colors 
indicate the z-score of the average counts per million of each gene in each cell type.
39
A) B)
Figure 4-3: DEGs which are in common between pairwise cell type comparisons. (A) shows 
genes which are upregulated in the first cell type listed, while (B) shows genes which are 
downregulated in the first cell type listed.
A) B)
Figure 4-4: DEGs which are in common among comparisons of each cell type against all other 
cell types. (A) shows genes which are upregulated against other cell types, while (B) shows 
genes which are downregulated against other cell types.
For each of the six comparisons mentioned above, heatmaps were generated showing the 
20 most significant DEGs in each direction across all involved samples, and these were then 
grouped within the heatmap by similarity of expression across rows. The heatmaps are shown in 
Figure 4-5.
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A) B) C)
D) E) F)
Figure 4-5: These are heatmaps showing the expression of the 20 most significant DEGs in each 
direction for each pairwise comparison made. Rows are grouped based on similarity across 
columns. Data is shown for each individual sample involved in that pairwise comparison.
D) In vitro/ in vitro comparison: Pathway analysis of differences between in vitro cell types 
in rats
Pathway analyses of the comparisons pictured in figure 4-5 A through C were performed 
using both GAGE and SPIA. The names, descriptions, and p-values of all significant pathways 
found by GAGE and SPIA respectively are listed in tables, followed by selected colored 
pathways charts generated by Pathview.
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Pathway p.val
rno05332 Graft-versus-host disease 0.000000003
rno05330 Allograft rejection 0.000000009
rno05320 Autoimmune thyroid disease 0.0000000978
rno04612 Antigen processing and presentation 0.0000001082
rno04510 Focal adhesion 0.0000002088
rno04060 Cytokine-cytokine receptor interaction 0.0000002348
rno04512 ECM-receptor interaction 0.0000002802
rno05416 Viral myocarditis 0.0000004761
rno04610 Complement and coagulation cascades 0.0000025050
rno04142 Lysosome 0.0000032991
rno05146 Amoebiasis 0.0000089427
rno05144 Malaria 0.0000105422
rno03010 Ribosome 0.0001841802
rno00982 Drug metabolism - cytochrome P450 0.0003615287
rno04350 TGF-beta signaling pathway 0.0004543827
rno04940 Type I diabetes mellitus 0.0005023512
rno04514 Cell adhesion molecules (CAMs) 0.0005234022
rno00980 Metabolism of xenobiotics by cytochrome P450 0.0009306151
rno04145 Phagosome 0.0012499831
rno04640 Hematopoietic cell lineage 0.0013147708
rno05323 Rheumatoid arthritis 0.0018811788
rno05322 Systemic lupus erythematosus 0.0020510053
rno04974 Protein digestion and absorption 0.0020750815
rno05200 Pathways in cancer 0.0022276506
rno00590 Arachidonic acid metabolism 0.002701593
rno05150 Staphylococcus aureus infection 0.0028988925
rno05140 Leishmaniasis 0.0034605152
rno04670 Leukocyte transendothelial migration 0.0034843081
rno00860 Porphyrin and chlorophyll metabolism 0.003752418
rno04620 Toll-like receptor signaling pathway 0.003769809
rno00480 Glutathione metabolism 0.0044779305
rno04630 Jak-STAT signaling pathway 0.00448487
rno04144 Endocytosis 0.0049129947
rno04520 Adherens junction 0.0056614053
rno00531 Glycosaminoglycan degradation 0.0060355516
rno04623 Cytosolic DNA-sensing pathway 0.0072793818
rno00040 Pentose and glucuronate interconversions 0.0084113703
rno04672 Intestinal immune network for IgA production 0.0116850392
rno00983 Drug metabolism - other enzymes 0.0128846527
rno05142 Chagas disease (American trypanosomiasis) 0.0134255765
rno00511 Other glycan degradation 0.0154540452
rno04141 Protein processing in endoplasmic reticulum 0.0158079713
rno00053 Ascorbate and aldarate metabolism 0.0175702463
rno00760 Nicotinate and nicotinamide metabolism 0.0196546401
rno05160 Hepatitis C 0.0202370331
rno05145 Toxoplasmosis 0.0236900626
rno00500 Starch and sucrose metabolism 0.0245643317
rno00830 Retinol metabolism 0.0249910976
rno05222 Small cell lung cancer 0.0251998534
rno04810 Regulation of actin cytoskeleton 0.0268862199
rno04621 NOD-like receptor signaling pathway 0.0270698123
rno04380 Osteoclast differentiation 0.033972731
rno05215 Prostate cancer 0.0362009454
rno04622 RIG-I-like receptor signaling pathway 0.0386237579
rno05143 African trypanosomiasis 0.0404023431
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rno05100 Bacterial invasion of epithelial cells 0.0406210472
rno04530 Tight junction 0.0444436181
rno00340 Histidine metabolism 0.0458340763
rno05220 Chronic myeloid leukemia 0.0484257796
rno04210 Apoptosis 0.0485755445
Table 4-4: GAGE pathway enrichment results between astrocytes and neurons. This table shows 
the names of all pathways significantly enriched between the two samples to a significance level 
of p<0.05.
Name ID P-value
Neuroactive ligand-receptor interaction 4080 3.07329287027726E-024
ECM-receptor interaction 4512 2.25446129029711E-013
Retrograde endocannabinoid signaling 4723 4.43031313777547E-013
Amoebiasis 5146 2.35926409508521E-009
Focal adhesion 4510 4.10468848356526E-009
Cytokine-cytokine receptor interaction 4060 1.04082432754351E-008
GABAergic synapse 4727 1.96616241871058E-007
Calcium signaling pathway 4020 2.66433290189066E-007
Glutamatergic synapse 4724 2.99528714194504E-007
Morphine addiction 5032 1.46223552153929E-006
Axon guidance 4360 2.56154461772565E-006
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 5412 5.80070885088937E-006
TNF signaling pathway 4668 7.05185589718525E-006
Cholinergic synapse 4725 8.26225960794004E-006
MAPK signaling pathway 4010 8.87554095726216E-006
Dilated cardiomyopathy 5414 1.87259156594522E-005
Type I diabetes mellitus 4940 2.85272365542126E-005
Graft-versus-host disease 5332 3.15412642468037E-005
Circadian entrainment 4713 4.00104798322369E-005
Malaria 5144 7.37367878833327E-005
Pertussis 5133 7.53646929915071E-005
PI3K-Akt signaling pathway 4151 7.76447121553292E-005
Allograft rejection 5330 9.29467049479692E-005
Salivary secretion 4970 0.0001208929
Basal cell carcinoma 5217 0.0001222042
Serotonergic synapse 4726 0.0001521034
Insulin secretion 4911 0.0001853173
Complement and coagulation cascades 4610 0.0001913106
Proteoglycans in cancer 5205 0.0001968632
Rap1 signaling pathway 4015 0.0002765209
Autoimmune thyroid disease 5320 0.0003248347
Chagas disease (American trypanosomiasis) 5142 0.0005336405
cAMP signaling pathway 4024 0.0008440887
Inflammatory bowel disease (IBD) 5321 0.0008758181
Salmonella infection 5132 0.0010872948
Dopaminergic synapse 4728 0.0010937157
Regulation of actin cytoskeleton 4810 0.0013167783
Hippo signaling pathway 4390 0.00136708
Oxytocin signaling pathway 4921 0.0014231938
43
Melanogenesis 4916 0.0016116522
Vascular smooth muscle contraction 4270 0.0024985923
Viral myocarditis 5416 0.0025731315
Platelet activation 4611 0.002956751
Chemokine signaling pathway 4062 0.0031712004
Antigen processing and presentation 4612 0.0032967821
Type II diabetes mellitus 4930 0.0045364104
Amyotrophic lateral sclerosis (ALS) 5014 0.0048212234
Ras signaling pathway 4014 0.0053916726
HTLV-I infection 5166 0.005856462
Rheumatoid arthritis 5323 0.0068452163
Tuberculosis 5152 0.0069668622
African trypanosomiasis 5143 0.0071106286
Legionellosis 5134 0.013234652
Leukocyte transendothelial migration 4670 0.0169926319
NOD-like receptor signaling pathway 4621 0.024776298
Leishmaniasis 5140 0.0254243775
Pancreatic secretion 4972 0.0259565609
Non-alcoholic fatty liver disease (NAFLD) 4932 0.031489168
Toll-like receptor signaling pathway 4620 0.0419067619
Estrogen signaling pathway 4915 0.044560232
Table 4-5: SPIA pathway enrichment results between astrocytes and neurons. This table shows 
the names of all pathways significantly enriched between the two samples to a significance level 
of p<0.05. This p-value is calculated by combining the p-values of the numbers of DEGs with 
the p-value of the accumulation of perturbation in the pathway. 
Several of these pathways were selected for further exploration, research, and explanation
in order to provide a coherent view at why the cells present different transcriptomes in the 
manner shown above. The pathways selected for closer examination were done so on the basis of
high significance, and previously found evidence of these pathways being involved in the cell 
types in question. The pathways examined for this comparison are the calcium signaling 
pathway[Grewal et al., 1999] (figure 4-6) and ECM-receptor interaction [Milner et al., 2002] 
(figure 4-7). Other pathways are also presented in Appendix A- for citations ergarding the 
pathways, see the KEGG page for the pathway. In these charts, red-colored genes indicate those 
genes with increased expression in astrocytes, while blue indicates increased expression in 
neurons. In many cases the results are self-explanatory- in figure 4-6, many genes which show 
increased expression in neurons are genes related to the production of calcium ions, which are 
needed for the membrane depolarization of an action potential. This pathway has previously been
shown to be significantly enriched in neurons [Cahoy et al., 2008]. Data in the opposite direction
is illustrated in Figure 4-9, which shows how many other genes involved with ECM interaction 
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Figure 4-6: Difference in expression of the calcium signaling pathway between astrocytes and 
neurons in rat cells in vitro. Red indicates genes more expressed in astrocytes, blue in neurons.
Figure 4-7: Difference in 
expression of the ECM-
receptor interaction 
pathway between 
astrocytes and neurons in 
rat cells in vitro. Red 
indicates genes more 
expressed in astrocytes, 
blue in neurons.
are also upregulated in astrocytes.
 A similar analysis was carried out comparing astrocytes with OPCs. The GAGE and 
SPIA pathways are shown in tables 4-6 and 4-7 respectively.
Pathway p.val
rno04510 Focal adhesion 3.00701222955865E-007
rno04512 ECM-receptor interaction 1.28038900882564E-006
rno04060 Cytokine-cytokine receptor interaction 2.28727074980988E-006
rno04610 Complement and coagulation cascades 2.54772957541032E-006
rno04640 Hematopoietic cell lineage 1.02271209601321E-005
rno05332 Graft-versus-host disease 1.82171947975172E-005
rno05330 Allograft rejection 2.58888215887163E-005
rno05146 Amoebiasis 2.73669027128534E-005
rno05320 Autoimmune thyroid disease 0.000032462
rno04145 Phagosome 4.38606182660206E-005
rno04612 Antigen processing and presentation 5.37177881070096E-005
rno05416 Viral myocarditis 9.70088097394853E-005
rno05144 Malaria 0.0001304827
rno00982 Drug metabolism - cytochrome P450 0.0001701415
rno05150 Staphylococcus aureus infection 0.0002846929
rno04142 Lysosome 0.00030002
rno05323 Rheumatoid arthritis 0.0006468994
rno04670 Leukocyte transendothelial migration 0.0006725302
rno00980 Metabolism of xenobiotics by cytochrome P450 0.0006971917
rno04672 Intestinal immune network for IgA production 0.0043414118
rno04380 Osteoclast differentiation 0.0044443855
rno05410 Hypertrophic cardiomyopathy (HCM) 0.0044692347
rno04940 Type I diabetes mellitus 0.004522284
rno05140 Leishmaniasis 0.004660193
rno00590 Arachidonic acid metabolism 0.0048615008
rno04350 TGF-beta signaling pathway 0.0049777852
rno04514 Cell adhesion molecules (CAMs) 0.005765729
rno04620 Toll-like receptor signaling pathway 0.0061245437
rno04974 Protein digestion and absorption 0.0071957618
rno05142 Chagas disease (American trypanosomiasis) 0.0076378745
rno04630 Jak-STAT signaling pathway 0.0096987157
rno04810 Regulation of actin cytoskeleton 0.0108520136
rno00480 Glutathione metabolism 0.0123689614
rno05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.0201503474
rno05145 Toxoplasmosis 0.0226864679
rno05414 Dilated cardiomyopathy 0.0253738442
rno00830 Retinol metabolism 0.0256751099
rno00860 Porphyrin and chlorophyll metabolism 0.0268112379
rno00140 Steroid hormone biosynthesis 0.0277690325
rno04621 NOD-like receptor signaling pathway 0.0278486375
rno04520 Adherens junction 0.0279745708
rno05200 Pathways in cancer 0.0293339627
rno04144 Endocytosis 0.0342456514
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rno00983 Drug metabolism - other enzymes 0.0424704825
rno04623 Cytosolic DNA-sensing pathway 0.0466000052
rno00531 Glycosaminoglycan degradation 0.049300726
Table 4-6: GAGE pathway enrichment results between astrocytes and OPCs. This table shows 
the names of all pathways significantly enriched between the two samples to a significance level 
of p<0.05.
Name ID p-value
Focal adhesion 4510 1.38421519222539E-012
Cytokine-cytokine receptor interaction 4060 1.56229538911204E-011
ECM-receptor interaction 4512 2.32622324869824E-011
Neuroactive ligand-receptor interaction 4080 4.33274515838219E-011
PI3K-Akt signaling pathway 4151 0.000000746
Complement and coagulation cascades 4610 1.40052531449438E-006
Amoebiasis 5146 2.6970744833687E-006
Proteoglycans in cancer 5205 3.38384221895463E-006
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 5412 8.61005720039904E-006
Antigen processing and presentation 4612 1.07834042730725E-005
Malaria 5144 0.000056907
Axon guidance 4360 0.0001733176
Graft-versus-host disease 5332 0.000184766
Basal cell carcinoma 5217 0.0002114821
TNF signaling pathway 4668 0.0002252596
Regulation of actin cytoskeleton 4810 0.0002259169
Hippo signaling pathway 4390 0.000302097
Allograft rejection 5330 0.0005431512
Ras signaling pathway 4014 0.0005869827
Autoimmune thyroid disease 5320 0.0014404913
Viral myocarditis 5416 0.0016006053
Legionellosis 5134 0.0016832378
Type I diabetes mellitus 4940 0.0019730011
Dilated cardiomyopathy 5414 0.0022785193
Pertussis 5133 0.0022844431
MAPK signaling pathway 4010 0.0038695569
Rap1 signaling pathway 4015 0.0045789606
Rheumatoid arthritis 5323 0.0062671987
Calcium signaling pathway 4020 0.0063625318
Chemokine signaling pathway 4062 0.0096508288
HTLV-I infection 5166 0.0167475713
Platelet activation 4611 0.020458923
GABAergic synapse 4727 0.022860501
Gap junction 4540 0.0231986574
Staphylococcus aureus infection 5150 0.0323132351
Pancreatic secretion 4972 0.0375959972
Hedgehog signaling pathway 4340 0.0381421595
Leukocyte transendothelial migration 4670 0.0384666556
Inflammatory bowel disease (IBD) 5321 0.0464805379
Melanogenesis 4916 0.0488556064
Natural killer cell mediated cytotoxicity 4650 0.0495719618
47
48
Figure 4-8: Difference in 
expression of the ECM-
receptor interaction 
pathway between astrocytes
and OPCs in rat cells in 
vitro. Red indicates genes 
more expressed in 
astrocytes, blue in OPCs.
Figure 4-9: 
Difference in 
expression of 
cell-cycle-related
genes between 
astrocytes and 
OPCs in rat cells
in vitro. Red 
indicates genes 
more expressed 
in astrocytes, 
blue in OPCs.
Table 4-7: SPIA pathway enrichment results between astrocytes and OPCs. This table shows the 
names of all pathways significantly enriched between the two samples to a significance level of 
p<0.05. This p-value is calculated by combining the p-values of the numbers of DEGs with the 
p-value of the accumulation of perturbation in the pathway. 
It should be noted that several of the same pathways are significantly different in this 
comparison as when comparing astrocyte/neuron expression. In particular, the ECM-receptor 
interaction (figure 4-8) pathway is very similar when comparing which genes are different, and 
how different they are. This means that the genes represented in those pathways as upregulated 
are indeed upregulated in that cell type compared to all of the neural cells measured, rather than 
simply downregulated in one of the cell types it is compared to. Additionally, the pathway  for 
the cell cycle is shown in figure 4-9, and it can be clearly seen that OPCs have a far more active 
cell cycle than astrocytes, something which also follows logically- as a type of semi-
differentiated stem cell, OPCs are able to generate certain types of glial cells while themselves 
continuing to reproduce and self-sustain, constituting a source of fresh cells for myelination and 
other functions. It is to be expected that OPCs are more reproductively active than astrocytes 
[Richardson et al., 2011].
The third comparison conducted between expression of cell types in in vitro neural tissue 
in rat is between neurons and OPCs. Similarly to the first two comparisons illustrated above, 
GAGE and SPIA were used to find significantly different pathways. These results are shown in 
tables 4-8 and 4-9 respectively.
Pathway p.value
rno04080 Neuroactive ligand-receptor interaction 1.83537649987241E-007
rno04020 Calcium signaling pathway 9.65126868231387E-005
rno04360 Axon guidance 0.0001890481
rno04010 MAPK signaling pathway 0.0052474724
rno04971 Gastric acid secretion 0.0166362574
rno04640 Hematopoietic cell lineage 0.0210286796
rno04540 Gap junction 0.0270465037
rno04970 Salivary secretion 0.028864329
rno00140 Steroid hormone biosynthesis 0.0308472775
rno05410 Hypertrophic cardiomyopathy (HCM) 0.0314395578
rno05150 Staphylococcus aureus infection 0.0350717493
rno05414 Dilated cardiomyopathy 0.0397656662
rno05014 Amyotrophic lateral sclerosis (ALS) 0.0426826103
rno04930 Type II diabetes mellitus 0.0463752297
rno04720 Long-term potentiation 0.047943512
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rno04742 Taste transduction 0.048158335
Table 4-8: GAGE pathway enrichment results between neurons and OPCs. This table shows the 
names of all pathways significantly enriched between the two samples.
Name ID p-value
Neuroactive ligand-receptor interaction 4080 6.33267599521586E-011
Axon guidance 4360 4.29723503574245E-010
Retrograde endocannabinoid signaling 4723 7.9007375830512E-006
Ras signaling pathway 4014 0.0001183561
Glutamatergic synapse 4724 0.0001731923
ECM-receptor interaction 4512 0.0006506711
Serotonergic synapse 4726 0.0007915077
Focal adhesion 4510 0.0008611562
Morphine addiction 5032 0.0010781791
GABAergic synapse 4727 0.0037976955
Dopaminergic synapse 4728 0.0041635117
Gap junction 4540 0.0048873919
Calcium signaling pathway 4020 0.0050331302
Cocaine addiction 5030 0.0067965308
Circadian entrainment 4713 0.0101038035
Long-term depression 4730 0.0122826349
Oxytocin signaling pathway 4921 0.0153835989
PI3K-Akt signaling pathway 4151 0.0170602811
Cholinergic synapse 4725 0.020617422
cAMP signaling pathway 4024 0.0238893909
Insulin secretion 4911 0.0291954252
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 5412 0.034318422
Amphetamine addiction 5031 0.0420889789
Aldosterone-regulated sodium reabsorption 4960 0.0474884126
Table 4-9: SPIA pathway enrichment results between neurons and OPCs. This table shows the 
names of all pathways significantly enriched between the two samples to a significance level of 
p<0.05. This p-value is calculated by combining the p-values of the numbers of DEGs with the 
p-value of the accumulation of perturbation in the pathway.
The pathway charts for calcium signaling,  and the cell cycle are shown below in figures 
4-10, and 4-11. The gene expression patterns in the calcium signaling and axon guidance charts 
show that these genes are indeed upregulated in neurons compared to the other cell types 
examined, and the expression in the cell cycle pathway shows that OPCs are indeed much more 
active in the cell cycle than either other cell type examined. It should be noted that in this 
comparison, neither GAGE nor SPIA indeed found the cell cycle to be significantly enriched- 
however, the genes shown within it in figure 4-15 are all significant to a level of q < 0.05, and so 
the genes involved may be used to illustrate differences in expression between the two cell types 
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Figure 4-10: Difference in expression of the calcium signaling pathway between neurons and 
OPCs in rat cells in vitro. Red indicates genes more expressed in neurons, blue in OPCs.
Figure 4-11: 
Difference in 
expression of 
cell-cycle-related
genes between 
neurons and 
OPCs in rat cells
in vitro. Red 
indicates genes 
more expressed 
in neurons, blue 
in OPCs.
despite the pathway itself not making the statistical cut.
E) In vitro/ in vitro comparison: Consistency between published annotation and cross-
species annotation
The basis of the cross-species comparisons made later within this manuscript hinge upon 
the assumption that the orthology-based cross-species annotation generated for the non-mouse 
species does in fact accurately represent the expression within the samples tested. To illustrate 
the consistency of results derived from this generated annotation, the comparisons mentioned 
above have been repeated using said annotation, and the orthologous KEGG pathways in mouse 
have been colored with expression values by cell type. It is to be expected that the pathways 
from the cross-species annotation will have fewer genes shown as differentially expressed, as 
significant numbers of genes and exons were cut from the mm10 annotation which served as its 
basis. Comparing figure 4-6 to figure 4-12, figure 4-7 to figure 4-13, and so on, it can be seen 
that among those genes which were indeed conserved during the generation of the cross-species 
annotation, expression within pathways is shown to be highly consistent. This is mildly further 
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Figure 4-12: Difference in expression of the calcium signaling pathway between astrocytes and 
neurons in rat cells in vitro, using the cross-species annotation. Red indicates genes more 
expressed in astrocytes, blue in neurons.
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Figure 4-13: Difference
in expression of the 
ECM-receptor 
interaction pathway 
between astrocytes and 
neurons in rat cells in 
vitro using the cross-
species annotation. Red
indicates genes more 
expressed in astrocytes,
blue in neurons.
Figure 4-14: 
Difference in 
expression of the ECM-
receptor interaction 
pathway between 
astrocytes and OPCs in
rat cells in vitro using 
the cross-species 
annotation. Red 
indicates genes more 
expressed in astrocytes,
blue in OPCs.
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Figure 4-15: Difference in expression of cell-cycle-related genes between astrocytes and OPCs 
in rat cells in vitro using the cross-species annotation. Red indicates genes more expressed in 
astrocytes, blue in OPCs.
Figure 4-16: Difference in expression of the calcium signaling pathway between neurons and 
OPCs in rat cells in vitro using the cross-species annotation. Red indicates genes more 
expressed in neurons, blue in OPCs.
supported by a similar comparison using human data in the next section. Furthermore, all of the 
pairwise pathway comparisons selected and shown here were indeed significantly (p < 0.05) 
differently expressed between the cell types in question using the cross-species annotation.
F) In vitro/ in vitro comparison: Differences in expression between in vitro human neural 
cells
The human samples were quantified against the hg38 annotation, and then compared 
against one another to quantify the differences in expression. Unlike the rat data, which had six 
samples across three difference cell types, the human data only has three samples across two cell 
types- two samples of astrocytes, and one of neurons. Since only one comparison- astrocyte 
versus neuron- can be made, a truncated version of the same analyses applied to the rat data were
applied to these samples. The top 200 genes expressed in the human samples were identified, and
a heatmap of these was produced, grouping rows by similarity of expression across columns. 
This heatmap is shown in figure 4-26. Additionally, a heatmap was made of the 40 most 
significantly differentially expressed genes comparing the two cell types, showing the 20 most 
significant genes in each direction, shown in figure 4-27. Since there is only one comparison, 
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Figure 4-17: Difference in expression of cell-cycle-related genes between neurons and OPCs in 
rat cells in vitro using the cross-species annotation. Red indicates genes more expressed in 
neurons, blue in OPCs.
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Figure 4-18: Difference in expression of the calcium signaling pathway between astrocytes and 
neurons in human cells in vitro. Red shows genes more expressed in astrocytes, blue in neurons.
Figure 4-19: 
Difference in 
expression of the 
ECM-receptor 
interaction pathway 
between astrocytes and
neurons in human cells
in vitro. Red indicates 
genes more expressed 
in astrocytes, blue in 
neurons.
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Figure 4-20: Difference in expression of the calcium signaling pathway between astrocytes and 
neurons in human cells in vitro using the cross-species annotation. Red indicates genes more 
expressed in astrocytes, blue in neurons.
Figure 4-21: Difference
in expression of the 
ECM-interaction 
pathway between 
astrocytes and neurons 
in human cells in vitro 
using the cross-species 
annotation. Red 
indicates genes more 
expressed in astrocytes,
blue in neurons.
unlike the rat data, it does not make sense to create Venn diagrams.
G) In vitro/ in vitro comparison: Pathway analysis of differences between in vitro cell types 
in humans
A pathway analysis was done to compare the expression data between the in vitro 
astrocyte and neuron samples of human data to quantify differences in expression in terms of 
biological processes. Significantly enriched KEGG pathways between astrocytes and neurons 
were tested using both SPIA and GAGE, and these pathways were then visualized using 
Pathview. Scraw. Several of these pathways were then selected for display and further 
examination. In an effort to show the similarity of expression between cell types across species 
in vitro, the same four pathways have been chosen for display as were shown in the rat samples 
between astrocytes and neurons: calcium signaling (figure 4-18) and ECM-receptor interaction 
(4-19). Additionally, table 4-10 and table 4-11 show the names and p-values of significantly 
enriched pathways according to GAGE and SPIA respectively.
Pathway p.value
hsa05200 Pathways in cancer 1.63719714996876E-023
hsa04510 Focal adhesion 1.33442952320779E-009
hsa04350 TGF-beta signaling pathway 6.31310896544157E-009
hsa05222 Small cell lung cancer 5.96155427648299E-007
hsa05146 Amoebiasis 1.12776895084513E-005
hsa04530 Tight junction 0.0001840087
hsa04630 Jak-STAT signaling pathway 0.0005678789
hsa04012 ErbB signaling pathway 0.0008353908
hsa04810 Regulation of actin cytoskeleton 0.0009685493
hsa04916 Melanogenesis 0.0018775965
hsa04020 Calcium signaling pathway 0.0021094405
hsa04520 Adherens junction 0.0023267521
hsa05414 Dilated cardiomyopathy 0.0023267521
hsa04270 Vascular smooth muscle contraction 0.0023267521
hsa04210 Apoptosis 0.004033723
hsa05215 Prostate cancer 0.0041631424
hsa04512 ECM-receptor interaction 0.0048975472
hsa04310 Wnt signaling pathway 0.006808502
hsa04910 Insulin signaling pathway 0.0161831421
hsa05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.0188977142
hsa04972 Pancreatic secretion 0.0194438063
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hsa04070 Phosphatidylinositol signaling system 0.020235566
hsa05220 Chronic myeloid leukemia 0.0317978025
hsa05410 Hypertrophic cardiomyopathy (HCM) 0.0355845124
hsa04062 Chemokine signaling pathway 0.0366130368
Table 4.10: Pathway names and p-values for significantly enriched pathways between astrocytes 
and neurons in humans according to GAGE
Name ID p-value
Huntington's disease 5016 6.94683003081565E-010
Parkinson's disease 5012 8.86828526568921E-008
Alzheimer's disease 5010 0.0001990188
Regulation of actin cytoskeleton 4810 0.0004715822
Bladder cancer 5219 0.0013795331
Non-alcoholic fatty liver disease (NAFLD) 4932 0.0015988699
Focal adhesion 4510 0.0045914426
Pathogenic Escherichia coli infection 5130 0.0058208172
Proteoglycans in cancer 5205 0.0060250334
Rheumatoid arthritis 5323 0.0075895909
Antigen processing and presentation 4612 0.0089817593
Staphylococcus aureus infection 5150 0.0104012927
MAPK signaling pathway 4010 0.0141833249
Renal cell carcinoma 5211 0.0147375044
Glioma 5214 0.0222826613
Vasopressin-regulated water reabsorption 4962 0.0228327459
FoxO signaling pathway 4068 0.0248485374
Pathways in cancer 5200 0.0268508511
Melanoma 5218 0.0273761102
MicroRNAs in cancer 5206 0.0300794915
Axon guidance 4360 0.0317007079
Gap junction 4540 0.0355358689
Dorso-ventral axis formation 4320 0.0385288448
Systemic lupus erythematosus 5322 0.0417056628
TGF-beta signaling pathway 4350 0.0454233583
Long-term depression 4730 0.0456562565
Table 4-11: SPIA pathway enrichment results between astrocytes and neurons in humans. This 
table shows the names of all pathways significantly enriched between the two samples to a 
significance level of p<0.05. This p-value is calculated by combining the p-values of the 
numbers of DEGs with the p-value of the accumulation of perturbation in the pathway. 
These KEGG pathways were also visualized between the same samples, using the cross-
species comparison generated for humans. However, there are some differences from the similar 
comparison made above with rat cells. There are quite a few fewer genes mapping to pathways 
than with the rat cross-species annotation, and the magnitude and sometimes even directionality 
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of the DEGs shown based on the cross-species annotation is different from the pathways 
generated using the hg38 annotation as above. Additionally, none of the four pathways above 
were significant using the cross species comparison- the pathway heatmaps were generated by 
manually entering the relevant pathway IDs. However, all genes colored on the pathway maps 
are indeed all significant to a q-value < 0.05. These pathway charts are the same respective 
pathways as above, and can be found in figures 4-18 through 4-21.
H) In vitro/ in vitro comparison: Summary
Based on the comparisons made, it can be shown that the expression between and within 
the cell types presented is consistent with previously published comparisons between these cell 
types, displaying marker genes and pathways which are known to be expressed in those cell 
types. The pathway differences make sense from a biological standpoint, both among those 
selected for diagram display as well as the other highly significant pathways. Furthermore, the 
pathway analysis and DEGs were shown to be quite similar in the rat comparison between the 
rnor5 gene annotation and the cross-species annotation, showing that the process for generating a
cross-species annotation works well at least within the rat samples- the human samples show 
markedly less similarity between the hg38 annotation results and the cross-species annotation 
results- this may indicate that humans are evolutionarily too far from rats and mice to reliably 
generate a high-quality cross-species genome annotation based on orthologous genome positions.
While other methods [Miller et al., 2010] have compared between mice and humans, their 
methods for finding consensus were different and less sensitive to evolutionary distance. For this 
reason, during the final comparisons between in vitro and in vivo, results and pathways will be 
shown only for the rat in vitro and mouse in vivo cells, after correcting for species-wide biases. 
Data for the comparison including humans will be shown in Appendix A.
I) In vitro/ in vivo comparison: Differences in gene expression between in vitro and in vivo
Once features were counted, the top 40 genes for each cell type within each species examined 
were found. Genes were sorted by log fold change, and genes with low expression were filtered 
out by selecting only genes which had a logCPM greater than 1.3, equivalent to a CPM of around
20. In the species with more than two cell types, the fold change was calculated by combining 
the expression data for all cell types which were not the one of interest. These top genes per cell 
type by species are presented in Table 4-12.
Presented in figure 4-22 are heatmaps representing the expression among all cell types 
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Figure 4-22 A: The top 200 genes by 
absolute expression across the 
experiment were selected, and the 
expression values for each is shown of
all cell types. Rows and columns are 
ordered by similarity.
Figure 4-22 B: The top 200 genes by 
absolute expression across the 
experiment were selected, and the 
expression values for each is shown 
of each data sample. Rows and 
columns are ordered by similarity.
and samples respectively. In both figures, the 200 genes with the highest expression across the 
whole experiment are shown , with their expression levels in each column shown by color. Both 
rows and columns are grouped by overall similarity, illustrated with a dendrogram. The black 
lines on each cell is merely a histogram, providing an additional visualization of the value of 
each cell to complement its color. The figures illustrate visible differences between samples and 
species, and may also be used to double-check the quality of the data- if a sample is 
exceptionally different from others in its group, it may be a target for additional scrutiny. This is 
mainly useful for assessing consistency within species among the most highly expressed genes 
and visualizing how different expression patterns in the other species are.
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Aldh1a7 Npas4 Enpp2 Got1l1 Igkv11-125 Cpsf7 Ints1 Atp13a1
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Serpina3c 4930506M07RikCspg4 Cdc42 Tmem252 Gm26794 Gm28289 Gm24649
Aldh1a1 Kcnk9 Sox10 Gm26995 Gm20397 1700086O06Rik Gm12632 Slc20a2
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Table 4-12: The top 40 genes expressed in each cell type compared against all other cell types 
within its species, sorted by log fold change. Genes with total expression logCPM less than 1.3 
have been removed.
Showing the top expressed genes for samples only illustrates certain aspects about that 
sample. When comparing samples to one another, it can be much more useful to compare the 
lists of all significantly differently expressed genes between two or more comparisons. Looking 
at the lengths of lists of DEGs can show at a glance whether two samples are distant from one 
another (and therefore have relatively high numbers of DEGs) or are more similar, and have 
fewer DEGs. These numbers can themselves be compared as well, using Venn diagrams for 
example. While simple overlap comparisons are not statistically rigorous and do not provide a 
quantitative measure of distance between two samples, Venn diagrams are very easy and intuitive
to understand and can then be used to illustrate interesting aspects of the data. Table 4-13 shows 
a number of comparisons with the numbers of differentially expressed genes between them, and 
Figure 4-23 contains Venn Diagrams showing the quantity of DEGs that some of these 
comparisons share. The high number of DEGs which are shared among all cell types in Figure 4-
23 indicate that there is a high degree of conservation among which genes are differentially 
expressed in vitro versus in vivo, implying that the difference affects the different cell types in 
much the same way. Note how in the species-corrected charts and tables, this is not the case. 
Further supporting this is Table 4-14, which shows the number of DEGs for in vitro/in vivo 
comparisons of comparisons between cell types within in vitro or in vivo. That is, for example, in
vitro astrocytes and neurons are compared to one another, and in vivo astrocytes and neurons are 
compared to one another. The results of these two comparisons are compared to each other for 
DEGs. This controls for the average differences between settings for the cell types examined, 
revealing which differences between cell types are not preserved across settings. A positive log 
fold change for a gene in the above example means that it is more expressed in in vitro astrocytes
or in vivo neurons than the other two cell types, and the inverse for a negative log fold change. 
The Venn diagrams in Figure 4-24 show how these data are consistent for each cell type. 
Essentially, what is shown here indicates that while many of the same genes are differentially 
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expressed in an in vitro setting compared to the same cell type in vivo in all three cell types, those
genes are differently expressed at significantly different levels across cell types.
In vitro vs in vivo All cell types Astrocyte Neuron OPC
Total DEGs 11830 11835 11497 12832
More expressed in vitro 4793 5122 4729 6642
More expressed in vivo 7037 6713 6768 6190
Table 4-13 A: The numbers of DEGs (q < 0.05) between in vitro and in vivo cell types, as well as
all cell types combined. The total number of DEGs is shown, and then broken down by the 
direction in which they are differently expressed.
R. norvegicus vs M. musculus All cell types Astrocyte Neuron OPC
Total DEGs 13748 12970 13219 12832
More expressed in vitro 7101 6708 6791 6642
More expressed in vivo 6647 6262 6428 6190
Table 4-13 B: The numbers of DEGs (q < 0.05) between in vitro and in vivo cell types,as well as 
all cell types combined, excluding human data. The total number of DEGs is shown, and then 
broken down by the direction in which they are differently expressed.
R. norvegicus vs M. musculus, species-corrected Astrocyte Neuron OPC
Total DEGs 2807 2571 1778
More expressed in vitro 1477 1096 813
More expressed in vivo 1330 1475 965
Table 4-13 C: The numbers of DEGs (q < 0.05) between in vitro and in vivo cell types in rats and
mice corrected for average species differences. The total number of DEGs is shown, and then 
broken down by the direction in which they are differently expressed.
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Figure 4-23: These Venn diagrams compare the DEGs shown in Table 4-13, showing the number 
of DEGs in common among the different comparisons. The top row shows the genes upregulated
in the in vitro/in vivo, rat/mouse, and corrected rat/mouse comparisons respectively. The bottom 
row shows genes downregulated in those same comparisons.
In vitro vs in vivo Ast vs Neu Ast vs OPC Neu vs OPC
Total DEGs 1940 5098 5175
Log FC > 0 1248 1719 1549
Log FC < 0 692 3379 3626
Table 4-14 A: The number of DEGs which are different between settings when comparing the 
results of comparisons between cell types within settings.
R. norvegicus vs M. musculus Ast vs Neu Ast vs OPC Neu vs OPC
Total DEGs 3042 2343 1887
Log FC > 0 1651 1256 915
LogFC < 0 1391 1087 972
Table 4-14 B: The number of DEGs which are different between settings when comparing the 
results of comparisons between cell types within settings, using only rat and mouse data.
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A) B)
C) D)
Figure 4-24: These Venn diagrams show similarities between comparisons between settings of 
comparisons across cell types within settings. In (A), the number shown is the number of genes 
significantly upregulated in the first cell type in vitro or the second cell type in vivo, while (B) 
shows the genes significantly upregulated in the second cell type in vitro or the first cell type in 
vivo. (C) and (D) show the same data as (A) and (B) respectively, but limit the in vitro data to 
only the rat datasets.
J) In vitro/ in vivo comparison: Pathway analysis of differences between settings in neural 
tissue: Astrocytes
The same analysis pipelines were used for downstream analysis here as were applied in 
earlier sections, and these results will be formatted similarly. There will also be presentation of 
some additional data to support certain observations made with regard to previously published 
data. First, GAGE and SPIA were used to examine significantly enriched pathways between the 
settings, the results of which are presented in table 4-15 and table 4-16 respectively.
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Name p.value
mmu04510 Focal adhesion 0.0008373788
mmu04512 ECM-receptor interaction 0.0011940708
mmu05322 Systemic lupus erythematosus 0.0017702126
mmu05410 Hypertrophic cardiomyopathy (HCM) 0.0116477713
mmu00590 Arachidonic acid metabolism 0.0142221262
mmu04380 Osteoclast differentiation 0.014404177
mmu05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.014470395
mmu00512 Mucin type O-Glycan biosynthesis 0.0149552317
mmu05144 Malaria 0.0160004138
mmu04142 Lysosome 0.0225967975
mmu05142 Chagas disease (American trypanosomiasis) 0.0272777774
mmu04350 TGF-beta signaling pathway 0.0273757933
mmu04610 Complement and coagulation cascades 0.0346088745
mmu05150 Staphylococcus aureus infection 0.0397687685
mmu05323 Rheumatoid arthritis 0.0445840522
mmu04060 Cytokine-cytokine receptor interaction 0.0464504089
mmu04623 Cytosolic DNA-sensing pathway 0.0478515833
Table 4-15: GAGE pathway enrichment results between in vitro rat cells and in vivo mouse cells 
in astrocytes, corrected for species averages. This table shows the names of all pathways 
significantly enriched between the two samples to a significance level of p<0.05.
Name ID p-value
Leishmaniasis 5140 0.0029970393
Focal adhesion 4510 0.0031290533
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 5412 0.0087905376
Malaria 5144 0.010428679
ECM-receptor interaction 4512 0.0138441248
Chagas disease (American trypanosomiasis) 5142 0.0164261482
TGF-beta signaling pathway 4350 0.0165152959
Neurotrophin signaling pathway 4722 0.0216386759
Cytosolic DNA-sensing pathway 4623 0.0235171382
HTLV-I infection 5166 0.0243480803
p53 signaling pathway 4115 0.0267844318
Tuberculosis 5152 0.0301036627
Salivary secretion 4970 0.0327244468
Non-alcoholic fatty liver disease (NAFLD) 4932 0.038339307
Apoptosis 4210 0.0392215392
Ras signaling pathway 4014 0.0406188981
Transcriptional misregulation in cancer 5202 0.0426365941
Proteoglycans in cancer 5205 0.0429569239
Prolactin signaling pathway 4917 0.0442497033
Pertussis 5133 0.0495088878
Table 4-16 A: SPIA pathway enrichment results between in vitro rat cells and in vivo mouse cells
in astrocytes, corrected for species averages. This table shows the names of all pathways 
significantly enriched between the two samples to a significance level of p<0.05.
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Figure 4-25: Difference 
in expression in the 
ECM-receptor 
interaction pathway 
between in vitro rat cells
and in vivo mouse cells, 
corrected for species 
averages. Red shows 
genes more expressed in 
rats, blue in mice.
Figure 4-27: Differences between 
the Notch signalling pathway in in 
vitro rat astrocytes and in vivo 
mouse astrocytes. Pathway is shown
before species average correction 
(top) and after (bottom).
Two pathways are then selected for closer examination: ECM-receptor interaction (figure 
4-25) and notch signaling (figure 4-26). There are several reasons for selecting these pathways- 
firstly, ECM-receptor interaction is selected for the same reason as it was above, thanks to its 
known involvement in astrocytes as well as its high significance in tables 4-15 and 4-16. The 
notch signaling pathway is chosen because it has previously been examined and discussed across
in vitro/in vivo settings [Cahoy et al., 2008] and the data presented allows for an expansion of 
that examination.
The Cahoy paper also published a list of the top 80 genes which were enriched in vitro 
over in vivo, and the top 80 enriched in vivo over in vitro. The expression for these genes are 
recorded in tables 4-17 and 4-18 respectively. Note that none of the tables containing this 
experiment's data lists all 80 genes- this is because not all of the genes of interest were included 
in the cross-species annotation.
Gene logFC logCPM FDR-adjusted p-value
ENSMUSG00000033715.9 -12.9124260667 5.2878098927 1.5652654387327E-063
ENSMUSG00000024989.9 -11.1928321878 7.6243137814 5.39825235234495E-061
ENSMUSG00000004665.5 9.634304725 6.7949343956 8.65687393049909E-045
ENSMUSG00000029484.8 -5.6397958897 5.3005766252 2.20841758734692E-040
ENSMUSG00000074802.5 8.4500205061 4.8245305333 1.00331471517222E-039
ENSMUSG00000062248.5 -8.5945965819 4.1371425747 7.10014327001427E-037
ENSMUSG00000024521.7 -7.5144496248 6.2174272664 9.96681288171922E-034
ENSMUSG00000042115.4 -8.5758326887 8.0813628016 5.16085966070404E-033
ENSMUSG00000020032.9 -5.4565024049 3.9624845968 3.544878217455E-028
ENSMUSG00000049630.5 13.2707851365 5.9161667625 7.92460416029225E-018
ENSMUSG00000032085.4 6.4188282765 3.9058898113 1.12144766399914E-017
ENSMUSG00000039405.6 9.3301856302 3.1849452392 7.82792826456485E-017
ENSMUSG00000047139.8 11.4478724137 8.2153427633 6.6023154737699E-016
ENSMUSG00000036169.5 8.9765343122 1.694938603 9.7186661293364E-016
ENSMUSG00000068220.5 -5.4409225059 8.3350205816 3.2808846841303E-015
ENSMUSG00000035683.8 7.9451011766 1.6469104602 2.20179069426831E-012
ENSMUSG00000030208.10 -4.8137837255 7.0005727794 2.90471736799602E-011
ENSMUSG00000021390.5 -5.9682171025 0.493274285 1.25240885492321E-010
ENSMUSG00000026365.10 -5.7745975928 1.4678549699 3.06889219990471E-010
ENSMUSG00000032487.8 -2.7574472085 5.0657357367 4.35410716750364E-010
ENSMUSG00000040605.6 2.558003339 4.9100579269 3.33126474241994E-009
ENSMUSG00000039004.5 7.1141009585 0.1802332822 1.50786849330001E-008
ENSMUSG00000031740.7 4.9330286713 0.4201243613 8.08351151184224E-008
ENSMUSG00000025789.4 7.9334201546 3.5037815998 8.97863775086076E-008
ENSMUSG00000037820.10 -2.8213947936 0.593062513 1.72427483660731E-007
ENSMUSG00000068196.4 4.8974229098 0.0860197682 1.89155169646703E-007
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ENSMUSG00000026051.8 3.6610828775 3.6013611073 1.81284803918474E-006
ENSMUSG00000027500.9 -4.2339820116 -0.7717362906 8.48154232192173E-006
ENSMUSG00000037725.7 -2.8145135747 4.4671241485 0.0082270412
ENSMUSG00000022206.6 4.6647483911 -0.3337966294 0.0135367207
ENSMUSG00000035493.9 -1.5329665223 0.6789820042 0.0253470078
ENSMUSG00000039116.4 2.811949795 5.7859471521 0.0326582196
ENSMUSG00000021186.8 -2.1497163983 7.761340882 0.0390090247
ENSMUSG00000032218.6 -0.8950012093 4.7157600458 0.1936417833
ENSMUSG00000024529.8 1.0465578606 7.6239506047 0.8936853309
ENSMUSG00000032291.8 2.9918186538 1.3596881778 0.9997141463
ENSMUSG00000020427.6 0.0179732953 6.6819569728 0.9997141463
ENSMUSG00000038587.8 6.7765858215 7.9461559051 0.9997141463
ENSMUSG00000022033.4 6.6328002171 3.937189514 0.9997141463
ENSMUSG00000023905.9 7.7788802587 5.8327478538 0.9997141463
ENSMUSG00000043091.8 9.587298414 11.8534381549 0.9997141463
ENSMUSG00000022324.9 5.3795474931 2.3687385011 0.9997141463
Table 4-17A: This table shows the expression of the genes listed by Cahoy as enriched in 
astrocytes in vitro. Data is shown for the in vitro/in vivo comparison of astrocytes. A positive 
logFC value indicates the gene was found to be more expressed in vitro, and negative in vivo.
Gene logFC logCPM FDR-adjusted p-value
ENSMUSG00000068220.5 6.216365452 8.3350205816 2.91975240567769E-038
ENSMUSG00000038587.8 6.5352832601 7.9461559051 4.43263309028606E-033
ENSMUSG00000030208.10 5.2763784172 7.0005727794 8.02158809787916E-031
ENSMUSG00000021186.8 6.3398253017 7.761340882 1.66297337303183E-030
ENSMUSG00000026051.8 5.5759771113 3.6013611073 3.35142937887659E-020
ENSMUSG00000037725.7 -4.642180873 4.4671241485 1.09331423181965E-015
ENSMUSG00000032085.4 4.7802201646 3.9058898113 5.87711866859075E-014
ENSMUSG00000024529.8 4.1839529946 7.6239506047 4.38653605727117E-012
ENSMUSG00000042115.4 3.3165738665 8.0813628016 6.84328989430647E-010
ENSMUSG00000024521.7 2.6357946311 6.2174272664 7.9992543229577E-010
ENSMUSG00000020427.6 2.9864652593 6.6819569728 2.18147962332473E-009
ENSMUSG00000039116.4 2.8067292143 5.7859471521 1.26111246863283E-007
ENSMUSG00000040605.6 2.1166252457 4.9100579269 1.45813965149602E-007
ENSMUSG00000074802.5 2.3659537883 4.8245305333 4.39036429385385E-005
ENSMUSG00000024989.9 -1.9312878359 7.6243137814 0.0001099364
ENSMUSG00000032487.8 1.5809821672 5.0657357367 0.0019189087
ENSMUSG00000021390.5 -2.4409924081 0.493274285 0.0022824265
ENSMUSG00000039004.5 2.4876866954 0.1802332822 0.0990762831
ENSMUSG00000035493.9 0.9799402836 0.6789820042 0.2949865708
ENSMUSG00000032218.6 -0.8867406012 4.7157600458 0.4278756244
ENSMUSG00000032291.8 -0.8466473597 1.3596881778 0.5360436062
ENSMUSG00000049630.5 1.4689355726 5.9161667625 0.5448174769
ENSMUSG00000022206.6 1.2365156829 -0.3337966294 0.5463050529
ENSMUSG00000043091.8 1.1178750118 11.8534381549 0.5945768918
ENSMUSG00000068196.4 0.9310042183 0.0860197682 0.6912265239
ENSMUSG00000062248.5 -0.7788899951 4.1371425747 0.7487469915
ENSMUSG00000029484.8 -0.4115781213 5.3005766252 0.8224563037
ENSMUSG00000020032.9 0.445422646 3.9624845968 0.9261240746
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ENSMUSG00000027500.9 -0.5037154236 -0.7717362906 0.9894078129
ENSMUSG00000026365.10 -0.4256682199 1.4678549699 0.9997531139
ENSMUSG00000033715.9 -0.5027496733 5.2878098927 0.9997531139
ENSMUSG00000031740.7 0.1770678314 0.4201243613 0.9997531139
ENSMUSG00000037820.10 -0.1183880474 0.593062513 0.9997531139
ENSMUSG00000004665.5 3.1926783892 6.7949343956 0.9997531139
ENSMUSG00000047139.8 2.2875944606 8.2153427633 0.9997531139
ENSMUSG00000036169.5 3.3969419937 1.694938603 0.9997531139
ENSMUSG00000022324.9 0.7194356684 2.3687385011 0.9997531139
ENSMUSG00000023905.9 2.7779770254 5.8327478538 0.9997531139
ENSMUSG00000025789.4 -1.9179369968 3.5037815998 0.9997531139
ENSMUSG00000039405.6 4.3373732657 3.1849452392 0.9997531139
ENSMUSG00000022033.4 2.5487163097 3.937189514 0.9997531139
ENSMUSG00000035683.8 -1.3709622246 1.6469104602 0.9997531139
Table 4-17B: This table shows the expression of the genes listed by Cahoy as enriched in 
astrocytes in vitro. Data is shown for the rat/mouse comparison of astrocytes, corrected for 
species averages. A positive logFC value indicates the gene was found to be more expressed in 
rats, and negative in mice.
Gene logFC logCPM FDR-adjusted p-value
ENSMUSG00000022658.10 -6.6727298697 4.2397418938 1.57788380281577E-046
ENSMUSG00000029307.6 -6.3160525038 4.4394598282 2.06937184840839E-046
ENSMUSG00000029838.8 -6.891370268 10.3692635751 4.78585131338199E-034
ENSMUSG00000003974.5 4.1130283823 6.7116645402 2.80673426418589E-022
ENSMUSG00000055782.8 -3.3411043051 4.9687552586 2.9427431028927E-022
ENSMUSG00000068748.4 11.3450868947 10.8355017925 2.68423787827601E-021
ENSMUSG00000026697.9 9.0015194901 2.1684287777 7.97325593760521E-020
ENSMUSG00000027221.5 8.6843590757 4.7607251758 1.18949915098019E-016
ENSMUSG00000021613.8 9.6576683108 3.0588701405 2.02006255839125E-016
ENSMUSG00000004892.8 11.982827698 8.9132953999 3.83404466155513E-015
ENSMUSG00000041261.9 8.0582870067 3.3321797964 1.85257323731813E-013
ENSMUSG00000001260.6 7.3694871772 0.1673021936 9.34186965012791E-011
ENSMUSG00000021364.10 7.9313565275 1.5936495513 8.61529246140492E-010
ENSMUSG00000033910.8 4.6491441016 4.4992582612 1.16125204858473E-009
ENSMUSG00000018500.2 8.2311365121 0.7815461363 2.14567023931636E-009
ENSMUSG00000000402.2 5.9702818777 -0.9551855813 0.000005873
ENSMUSG00000030235.12 2.7509867056 2.5780334819 6.86584394041893E-006
ENSMUSG00000020591.10 3.8537686296 5.0849245652 2.07787667505154E-005
ENSMUSG00000049612.10 -4.0720191645 -0.3966031122 4.63627593978514E-005
ENSMUSG00000007682.5 7.7376126495 3.2105733415 0.0001361552
ENSMUSG00000026614.6 5.4652325052 4.0238536627 0.0006215707
ENSMUSG00000039037.5 6.7592615916 1.9532892075 0.0006576552
ENSMUSG00000032482.5 -1.4539678268 7.7533654822 0.0025634473
ENSMUSG00000033208.7 1.4699308297 1.5711263893 0.0538141857
ENSMUSG00000021536.7 -0.7324676713 1.705750307 0.1225627389
ENSMUSG00000078202.3 -0.5084281857 4.9010968497 0.5560962209
ENSMUSG00000000560.5 1.9943063175 4.5956491053 0.9997141463
ENSMUSG00000021719.8 5.338005329 3.2918903881 0.9997141463
ENSMUSG00000062151.8 4.9355480073 1.8176584953 0.9997141463
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ENSMUSG00000050505.6 3.6420977262 5.1406556021 0.9997141463
ENSMUSG00000039194.10 3.7506717842 6.1277671588 0.9997141463
ENSMUSG00000026259.9 3.8409646199 2.4763759577 0.9997141463
Table 4-18A: This table shows the expression of the genes listed by Cahoy as enriched in 
astrocytes in vivo. Data is shown for the in vitro/in vivo comparison of astrocytes. A positive 
logFC value indicates the gene was found to be more expressed in vitro, and negative in vivo.
Gene logFC logCPM FDR-adjusted p-value
ENSMUSG00000032482.5 -3.5480341694 7.7533654822 2.11051819575502E-011
ENSMUSG00000021536.7 -1.6526741165 1.705750307 0.0005369356
ENSMUSG00000029307.6 -1.4783104393 4.4394598282 0.0015858896
ENSMUSG00000049612.10 -1.9761686399 -0.3966031122 0.0148213486
ENSMUSG00000078202.3 1.5676349947 4.9010968497 0.0366942269
ENSMUSG00000030235.12 1.266213626 2.5780334819 0.0591519647
ENSMUSG00000020591.10 -1.5396382277 5.0849245652 0.1472083579
ENSMUSG00000027221.5 1.8382267115 4.7607251758 0.2558968775
ENSMUSG00000003974.5 -0.5779553538 6.7116645402 0.2815536082
ENSMUSG00000022658.10 0.6266014771 4.2397418938 0.3977021235
ENSMUSG00000029838.8 -0.5815912135 10.3692635751 0.5431815482
ENSMUSG00000000560.5 -0.7024220233 4.5956491053 0.623464355
ENSMUSG00000033910.8 -0.6671795814 4.4992582612 0.7323794649
ENSMUSG00000068748.4 -0.8466287464 10.8355017925 0.9997531139
ENSMUSG00000033208.7 -0.246303079 1.5711263893 0.9997531139
ENSMUSG00000055782.8 0.0027165446 4.9687552586 0.9997531139
ENSMUSG00000000402.2 -0.6298022259 -0.9551855813 0.9997531139
ENSMUSG00000021613.8 -0.6105486745 3.0588701405 0.9997531139
ENSMUSG00000001260.6 -0.7924660209 0.1673021936 0.9997531139
ENSMUSG00000026259.9 -1.7390558259 2.4763759577 0.9997531139
ENSMUSG00000021364.10 0.016803913 1.5936495513 0.9997531139
ENSMUSG00000018500.2 2.1303617777 0.7815461363 0.9997531139
ENSMUSG00000039194.10 -3.6142422015 6.1277671588 0.9997531139
ENSMUSG00000007682.5 0.5509112667 3.2105733415 0.9997531139
ENSMUSG00000050505.6 -2.9146066165 5.1406556021 0.9997531139
ENSMUSG00000041261.9 -1.0555432245 3.3321797964 0.9997531139
ENSMUSG00000026697.9 -0.6238840087 2.1684287777 0.9997531139
ENSMUSG00000039037.5 1.4698389961 1.9532892075 0.9997531139
ENSMUSG00000021719.8 -0.7018288927 3.2918903881 0.9997531139
ENSMUSG00000062151.8 -0.2246040449 1.8176584953 0.9997531139
ENSMUSG00000026614.6 -3.6382179483 4.0238536627 0.9997531139
ENSMUSG00000004892.8 -0.8070941659 8.9132953999 0.9997531139
Table 4-18B: This table shows the expression of the genes listed by Cahoy as enriched in 
astrocytes in vivo. Data is shown for the rat/mouse comparison of astrocytes, corrected for 
species averages. A positive logFC value indicates the gene was found to be more expressed in 
rats, and negative in mice.
It can be clearly seen from tables 4-17 and 4-18 that the expression values of previously 
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published genes which were enriched in one setting or the other do not follow their previously 
reported expression in this experiment- many of what were the most significantly different genes 
in the Cahoy paper are not significantly different here, or may even be significantly different in 
the opposite direction. There are a number of possible explanations for this discrepancy: firstly, 
the Cahoy experiment used microarrays, while these reported data are from RNAseq. Any bias 
present in either experiment may have skewed the results found in these genes in either direction,
and it has certainly been previously shown that microarray and RNAseq analysis of the same 
samples can result in very different results [Liu et al., 2011]. Furthermore, the Cahoy in vitro 
astrocytes were in fact astrocytes which were freshly harvested from the mouse brain, and then 
cultured for five days before sequencing. The astrocytes used in this experiment were ordered, 
frozen and pre-isolated, from a supplier, and then were thawed and cultured for ten days before 
sequencing was performed. The difference in physical treatment of the cells may well be 
responsible for this marked difference in expression.
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Figure 4-27: Difference in expression of morphine addiction-related genes between in vitro rat 
and in vivo mouse neurons, corrected for species averages.
K) In vitro/ in vivo comparison: Pathway analysis of differences between settings in neural 
tissue: Neurons
Neurons were analyzed in a similar manner to the astrocytes mentioned above. However, 
unique among the three cell types analyzed, a prior transcriptomic analysis comparing these cells
in vitro/in vivo was not found in the literature- for this reason the results and discussion are more 
limited. Pathway analysis was conducted with GAGE and SPIA, the significant results of which 
are shown in table 4-19 and 4-20 respectively. The pathway maps for morphine addiction are 
then shown in figure 4-27. Additional pathway maps are shown in Appendix A.
Pathway p.value
mmu04740 Olfactory transduction 8.45751834736977E-005
mmu04080 Neuroactive ligand-receptor interaction 0.0105825511
mmu04540 Gap junction 0.0253766345
mmu01040 Biosynthesis of unsaturated fatty acids 0.0474577624
mmu04971 Gastric acid secretion 0.0618313762
mmu04950 Maturity onset diabetes of the young 0.1017910168
mmu04020 Calcium signaling pathway 0.1074571664
mmu04914 Progesterone-mediated oocyte maturation 0.107891391
mmu04514 Cell adhesion molecules (CAMs) 0.1264973921
mmu04940 Type I diabetes mellitus 0.1273116821
mmu04912 GnRH signaling pathway 0.1296689416
mmu05340 Primary immunodeficiency 0.1371473616
mmu05310 Asthma 0.1842385058
mmu00604 Glycosphingolipid biosynthesis - ganglio series 0.1869630299
mmu04916 Melanogenesis 0.1873834677
mmu04730 Long-term depression 0.1927054145
mmu00534 Glycosaminoglycan biosynthesis - heparan sulfate 0.1954235382
mmu05330 Allograft rejection 0.2011771601
mmu04960 Aldosterone-regulated sodium reabsorption 0.2191424479
mmu04140 Regulation of autophagy 0.2267125497
mmu04722 Neurotrophin signaling pathway 0.2273195087
mmu05320 Autoimmune thyroid disease 0.2277358555
mmu04720 Long-term potentiation 0.2293782643
mmu04260 Cardiac muscle contraction 0.2330715942
mmu04742 Taste transduction 0.2489005027
mmu04973 Carbohydrate digestion and absorption 0.2495397652
mmu04966 Collecting duct acid secretion 0.2514447946
mmu04145 Phagosome 0.2539999516
mmu04970 Salivary secretion 0.2630768613
mmu04062 Chemokine signaling pathway 0.2734150862
mmu05150 Staphylococcus aureus infection 0.3132503477
mmu00564 Glycerophospholipid metabolism 0.3339597712
mmu04340 Hedgehog signaling pathway 0.3517586614
mmu05012 Parkinson's disease 0.3637449946
mmu04664 Fc epsilon RI signaling pathway 0.3650984702
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mmu03320 PPAR signaling pathway 0.3685758782
mmu04622 RIG-I-like receptor signaling pathway 0.3708679366
mmu05416 Viral myocarditis 0.3766625065
mmu04614 Renin-angiotensin system 0.3820733085
mmu00982 Drug metabolism - cytochrome P450 0.3883338081
mmu04930 Type II diabetes mellitus 0.3900023248
mmu03015 mRNA surveillance pathway 0.3903585739
mmu00350 Tyrosine metabolism 0.4042105443
mmu00601 Glycosphingolipid biosynthesis - lacto and neolacto series 0.4081708598
mmu05217 Basal cell carcinoma 0.4087053451
mmu00500 Starch and sucrose metabolism 0.4131783596
mmu04360 Axon guidance 0.4247743231
mmu05160 Hepatitis C 0.4440689339
mmu05020 Prion diseases 0.4464479395
mmu04270 Vascular smooth muscle contraction 0.4480189992
mmu04976 Bile secretion 0.4562073549
mmu00270 Cysteine and methionine metabolism 0.4582749273
mmu00650 Butanoate metabolism 0.458696163
mmu04010 MAPK signaling pathway 0.4631324046
mmu02010 ABC transporters 0.4681975035
mmu04070 Phosphatidylinositol signaling system 0.473296118
mmu00561 Glycerolipid metabolism 0.4768888382
mmu04630 Jak-STAT signaling pathway 0.4836118558
mmu04672 Intestinal immune network for IgA production 0.4953559177
Table 4-19: GAGE pathway enrichment results between in vitro rat and in vivo mouse neurons, 
corrected for species averages. This table shows the names of all pathways significantly enriched
between the two samples to a significance level of p<0.05.
Name ID p-value
Malaria 5144 0.0125531598
HTLV-I infection 5166 0.0196970232
Salivary secretion 4970 0.0213113198
Chagas disease (American trypanosomiasis) 5142 0.0216439341
Morphine addiction 5032 0.0228036698
Amphetamine addiction 5031 0.0421627606
Hippo signaling pathway 4390 0.0550885883
Cell cycle 4110 0.0564334168
Estrogen signaling pathway 4915 0.0566115914
Gap junction 4540 0.0650902636
Dilated cardiomyopathy 5414 0.0699569546
Bacterial invasion of epithelial cells 5100 0.0736472154
Circadian rhythm 4710 0.0763362519
Neurotrophin signaling pathway 4722 0.0779469158
Transcriptional misregulation in cancer 5202 0.084426284
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 5412 0.099250952
Table 4-20: SPIA pathway enrichment results between rats and mice in neurons. This table 
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shows the names of all pathways significantly enriched between the two samples to a 
significance level of p<0.05.
L) In vitro/ in vivo comparison: Pathway analysis of differences between settings in neural 
tissue: OPCs
The third and final cell type to be compared in vitro/in vivo is oligodendrocyte progenitor 
cells. Unlike the previous two, there are no human OPC samples in this experiment. GAGE and 
SPIA pathway data are shown in table 4-21 and table 4-22. Following these, pathway maps for 
the cell cycle (figure 4-28) will be shown.
Pathway p.value
mmu03040 Spliceosome 0.0069969173
mmu04110 Cell cycle 0.030783513
mmu04972 Pancreatic secretion 0.0334237531
mmu00190 Oxidative phosphorylation 0.0449455488
mmu04120 Ubiquitin mediated proteolysis 0.0508828432
mmu05223 Non-small cell lung cancer 0.0555511392
mmu00600 Sphingolipid metabolism 0.0619847292
mmu04664 Fc epsilon RI signaling pathway 0.0636661759
mmu03022 Basal transcription factors 0.071396001
mmu00565 Ether lipid metabolism 0.0867563716
mmu00020 Citrate cycle (TCA cycle) 0.0896597453
mmu04910 Insulin signaling pathway 0.0902532046
mmu04370 VEGF signaling pathway 0.0932008263
mmu00240 Pyrimidine metabolism 0.1009503806
mmu00230 Purine metabolism 0.117654293
mmu03010 Ribosome 0.1246385176
mmu04975 Fat digestion and absorption 0.1278294213
mmu03050 Proteasome 0.1284460954
mmu03013 RNA transport 0.1317833958
mmu05012 Parkinson's disease 0.13431686
mmu05016 Huntington's disease 0.1359629772
mmu04330 Notch signaling pathway 0.1377987023
mmu00970 Aminoacyl-tRNA biosynthesis 0.1484080598
mmu03420 Nucleotide excision repair 0.1577799483
mmu05221 Acute myeloid leukemia 0.170094775
mmu04912 GnRH signaling pathway 0.1739458596
mmu03018 RNA degradation 0.1782004428
mmu00561 Glycerolipid metabolism 0.1879490566
mmu00270 Cysteine and methionine metabolism 0.1903429263
mmu00250 Alanine, aspartate and glutamate metabolism 0.1979631712
mmu04930 Type II diabetes mellitus 0.2109511069
mmu04520 Adherens junction 0.2138210919
mmu00983 Drug metabolism - other enzymes 0.230377301
mmu04012 ErbB signaling pathway 0.2431704621
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mmu04115 p53 signaling pathway 0.2447389068
mmu05010 Alzheimer's disease 0.2476143319
mmu05212 Pancreatic cancer 0.2581842283
mmu00564 Glycerophospholipid metabolism 0.258359411
mmu04977 Vitamin digestion and absorption 0.2602477093
mmu04730 Long-term depression 0.2605485864
mmu03060 Protein export 0.2674201559
mmu05219 Bladder cancer 0.2754306691
mmu00603 Glycosphingolipid biosynthesis - globo series 0.2891691931
mmu00860 Porphyrin and chlorophyll metabolism 0.2921937199
mmu03008 Ribosome biogenesis in eukaryotes 0.29513903
mmu00601 Glycosphingolipid biosynthesis - lacto and neolacto series 0.2957582419
mmu03020 RNA polymerase 0.2978167494
mmu04966 Collecting duct acid secretion 0.306586332
mmu00620 Pyruvate metabolism 0.3076902979
mmu03410 Base excision repair 0.3190576096
mmu05213 Endometrial cancer 0.3223006683
mmu00640 Propanoate metabolism 0.3323807279
mmu05020 Prion diseases 0.3623597571
mmu00260 Glycine, serine and threonine metabolism 0.3686296118
mmu04950 Maturity onset diabetes of the young 0.3691779099
mmu04744 Phototransduction 0.374319414
mmu00330 Arginine and proline metabolism 0.3771138659
mmu04130 SNARE interactions in vesicular transport 0.3785173545
mmu00562 Inositol phosphate metabolism 0.3844967932
mmu05160 Hepatitis C 0.3922439935
mmu05100 Bacterial invasion of epithelial cells 0.3939398431
mmu04666 Fc gamma R-mediated phagocytosis 0.3948987495
mmu04920 Adipocytokine signaling pathway 0.3985031407
mmu04140 Regulation of autophagy 0.4255714763
mmu04150 mTOR signaling pathway 0.4423476351
mmu05214 Glioma 0.4665861318
mmu00531 Glycosaminoglycan degradation 0.4715434831
mmu04070 Phosphatidylinositol signaling system 0.4786232924
mmu04141 Protein processing in endoplasmic reticulum 0.4793169877
mmu03015 mRNA surveillance pathway 0.4951944503
mmu03320 PPAR signaling pathway 0.4955288811
mmu04142 Lysosome 0.499192659
Table 4-21: GAGE pathway enrichment results between rats and mice in OPCs, corrected for 
species averages. This table shows the names of all pathways significantly enriched between the 
two samples to a significance level of p<0.05.
Name ID p-value
Systemic lupus erythematosus 5322 4.30718881226101E-005
Malaria 5144 0.0005192691
ECM-receptor interaction 4512 0.0013445283
Proteoglycans in cancer 5205 0.0106412399
PI3K-Akt signaling pathway 4151 0.0152221238
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 5412 0.0182329949
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Focal adhesion 4510 0.0226656859
Cell cycle 4110 0.0288560759
Pancreatic cancer 5212 0.035123647
Glutamatergic synapse 4724 0.0354632617
Viral myocarditis 5416 0.0499980622
Table 4-22: SPIA pathway enrichment results between rats and mice in OPCs, corrected for 
species averages. This table shows the names of all pathways significantly enriched between the 
two samples to a significance level of p<0.05.
A previously published paper [Dugas et al., 2006] made a comparison of in vitro and in vivo 
OPCs using microarrays, and concluded that for many aspects of the expression profile of the 
cell- in particular myelin-related genes- were very similar in terms of expression to OPCs in vivo.
In fact, previous data suggests that OPCs should generally be nearly identical in vitro to in vivo 
counterparts [Baumann et al, 2001]. However, this appears to not be the case for the cells 
presented here- for example, the myelin-related genes mentioned in the Dugas paper were 
examined in this comparison and are shown in table 4-23. As can be seen, of the seven relevant 
genes to make it into the cross-species annotation, only three were not shown to be significantly 
differentially expressed- but this changes drastically in table 4-23B, where after correcting for 
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Figure 4-28: 
Difference in 
expression of cell 
cycle-related 
pathways between 
rat and mouse 
OPCs correcting for
species averages. 
Red indicates genes 
more expressed in 
rats, blue in mice.
species averages, only one gene remains significantly differently expressed. This illustrates the 
importance of correcting for species averages, as bias introduced in this manner has a huge effect
on whether or not the data resembles previously published data for the cell types in question.
Gene logFC logCPM FDR-adjusted p-value
ENSMUSG00000037625.6 -9.0194770279 7.6870443647 1.8637838069412E-054
ENSMUSG00000032854.8 10.2755037954 6.9784753023 1.23270503409118E-033
ENSMUSG00000027858.8 4.9205982829 1.5056869746 4.87760700042238E-010
ENSMUSG00000076439.7 -5.4227081358 0.9174398965 4.79218827354167E-008
ENSMUSG00000032517.10 -1.5728853564 0.5586784917 0.1391799949
ENSMUSG00000027375.9 -1.4092930124 0.893084531 0.2107252262
ENSMUSG00000031775.4 -0.369962467 0.0672180854 0.725939383
Table 4-23A: Expression information regarding the myelin-related genes examined by Dugas. A 
positive logFC indicates increased expression in OPCs in rats, a negative value in mice.
Gene logFC logCPM FDR-adjusted p-value
ENSMUSG00000032854.8 4.5486593295 6.9784753023 4.34329959234785E-014
ENSMUSG00000032517.10 -1.7882821962 0.5586784917 0.2257689803
ENSMUSG00000027858.8 1.2225656308 1.5056869746 0.2368827654
ENSMUSG00000031775.4 1.1474207249 0.0672180854 0.4456698265
ENSMUSG00000027375.9 0.9115189278 0.893084531 0.8542662111
ENSMUSG00000076439.7 -0.6048902674 0.9174398965 0.9998174978
ENSMUSG00000037625.6 0.17318373 7.6870443647 0.9998174978
Table 4-23B: Expression information regarding the myelin-related genes examined by Dugas, 
corrected for differences between species. A positive logFC indicates increased expression in 
OPCs in rats, a negative value in mice.
M) In vitro/ in vivo comparison: Summary
After in vitro/in vivo comparisons of all three cell types examined, numerous pathways 
were found to be significantly differently expressed between the two. After consultation with 
previously published work, the astrocyte expression was found to follow reasonably well the 
models previously made describing astrocyte gene expression in vitro, with a couple of 
exceptions. The numerous differences between cell types indicates that care should be taken 
when selecting in vitro cells to use in place of in vivo cells for the same purpose, and neural cells 
absolutely behave significantly differently in vitro than they do in the brain itself. However, 
confounding effects present in this analysis should also be accounted for, which are discussed in 
the discussion section.
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Section 5
Discussion and future work: Implications of different expression of neural cell types in vitro
compared to the same cell types in vivo using the developed protocol.
Gene expression and pathway among cell types in rats have shown that the rat cells raised
in vitro for this experiment indeed exhibit fairly usual and canonical expression pathways in the 
cell types in question, indicating that they are likely to indeed be good representative models of 
in vitro cells of their own cell types. Lists of genes and pathways demonstrated to be 
significantly different in pairwise comparisons of the samples constitute the first publication of 
comparisons of transcription between these cell types in rats.
Similar analyses conducted on the same samples using the cross-species annotation 
indicate that the cross-species annotation generated for rats reflects the true expression within the
cells examined quite well, and therefore is fit to be compared to other samples using the same 
annotation. When the human in vitro samples were analyzed in a similar way, it was found that 
the cross-species annotation did not reflect the true expression within the samples nearly as well 
as was the case with rats. As the generation of the cross-species annotation is a pair-wise genome
alignment based on orthology, it will become worse as evolutionary distance from the base 
species to the target species increases- this shows that while rats are suitably closely related to 
mice for the cross-species comparison to work well, the human is not so robust, something which
should be considered when performing cross-species comparisons in the future.
Comparisons were then presented quantifying differences in expression of these cell 
types in vivo against the rat and human in vitro data. Due to the finding that the human data did 
not translate as well across species, each of these comparisons were made using, in turn, all in 
vitro data, and only the rat subset of the in vitro data. This enables the presentation of as much 
data as possible while still presenting data which remains valid despite the possibility that the 
human data is not useful for this purpose. It has previously been established that humans and 
mice neural tissue presents significantly different transcriptomic profiles among orthologous 
genes.
Unfortunately, one of the major limitations of this method is its inability to control for 
evolutionary differences across species in cell types which are not shared with other cell types 
within that species. This means that when reporting results regarding which genes are different 
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between in vitro rat cells and in vivo mouse cells, those differences could be due to the difference
in cell setting, or due to differences introduced by evolutionary divergence. Factors which affect 
all of the cells examined in similar ways, such as bias introduced by the cross-species annotation,
can be controlled for by correcting gene expression by the species average. However, if any 
genes are different between species in only one cell type, it cannot be reliably controlled for 
without the inclusion of, for example, in vitro mouse samples of that cell type, or in vivo rat 
samples. Future work may include these to robustly determine the differences in vitro and in vivo
in these cell types using the data already generated.
It can be seen from tables 4-13 and 4-14 that the inclusion of the human data has a 
definite skewing effect on the results of the differential expression analyses. The human dataset 
does not include any samples of OPC cells- which leaves OPC comparisons free from any effect 
that the human data may have. This is illustrated well in figure 4-23, where when comparing 
DEG lists of genes upregulated in vitro, there are over two thousand DEGs upregulated in OPCs 
in vitro that are not significantly different in astrocytes or neurons. This effect is likely due to the 
human data having a “fuzzing” effect on the rat data- as can be seen in figure 4-22B, the 
dendrogram actually places the mouse and rat data closer together in terms of similarity of 
expression than to the human data. In terms of differential expression analysis, combining these 
dissimilar samples will reduce the CPM values for all genes with different expression between 
these samples. This makes it more difficult for genes to show up as upregulated in vitro when 
human data is included- though as can be seen from figure 4-23, this fuzzing effect does not 
affect the number of upregulated genes in mice. Figure 4-24 can be difficult to understand and 
interpret. Since each comparison listed with DEGs is actually the result of the comparison of the 
results of two different other comparisons- one in vitro, the other in vivo, one cannot look at a 
number and state definitively that it is upregulated in one particular cell type. Rather, a positive 
logFC value indicates that the gene in question is upregulated either in the first cell type of the 
first comparison, or the second cell type of the second comparison- the only way to tell which is 
to examine the expression CPM values in the constituent comparisons. The reason for these 
comparisons is to cause a deliberate, controlled version of the “fuzzing” described above to test 
whether the shift from an in vitro to in vivo setting affects all of the cell types examined in the 
same way. If in vitro astrocytes were different from in vivo astrocytes in the same way that in 
vitro neurons were different from in vivo neurons, then these comparisons will test this by 
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essentially combining the expression values of the in vitro astrocytes with those of the in vivo 
neurons, and comparing this against the combined expression values of the in vitro neurons and 
in vivo astrocytes. This controls both for differences across settings and across cell types, so if 
the setting difference between the two cell types was the same, then one would expect to see 
close to zero DEGs as a result. As is shown in table 4-14, while the numbers of DEGs are much 
lower than those shown in table 4-13, there are still thousands of DEGs between the 
comparisons, from which it may be concluded that a change in setting will have variable effects 
on different cell types.
Comparisons of in vitro astrocytes against in vivo astrocytes showed that many pathways 
previously shown to be different between cells raised in the two different settings, and the Notch 
pathway in particular was shown to have different expression between settings in a way mostly 
consistent with previous results. Other pathways shown to be differently expressed include a 
large number of pathways involved in the cell's interaction with its extracellular surroundings, as 
well as pathways involved in diseases such as Alzheimer's disease. Differences in many of these 
same pathways were also shown to be present in neurons, as well as other pathways indicating 
significant changes in metabolism, morphology, and intercellular connectivity.
Data presented for oligodendrocyte progenitor cells agrees less robustly with previously 
published examinations of in vitro OPCs against in vivo, which found little to no difference in 
cell expression regardless of setting. To the contrary, this experiment shows setting-dependent 
expression difference in OPCs in the thousands of DEGs, though the number of DEGs is indeed 
much lower than either of the other two cell types examined. In table 4-23, it can be seen that 
especially after correcting for species averages, myelin-related genes are indeed 
Future work may involve the sequencing of mouse cells raised in vitro, which would 
provide data to verify the results of the comparisons shown above compared across species- 
these samples would allow for additional robustness in the in vitro/in vivo comparison as well as 
providing an opportunity for the quantification of the quality of the cross-species comparison 
performed. Additionally, further downstream analysis may be applied to the existing body of data
to subset it further and derive more meaning from the comparisons already made.
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Appendix A
1
Figure A-1: Difference in expression of the axon guidance pathways between astrocytes and 
neurons in rat cells in vitro. Red indicates genes more expressed in astrocytes, blue in neurons.
Figure A-2: Difference in expression of the focal adhesion pathway between astrocytes and 
neurons in rat cells in vitro. Red indicates genes more expressed in astrocytes, blue in neurons.
2Figure A-3: Difference in expression of the focal adhesion pathway between astrocytes and 
OPCs in rat cells in vitro. Red indicates genes more expressed in astrocytes, blue in OPCs.
Figure A-4: Difference in expression of the axon guidance pathways between neurons and OPCs
in rat cells in vitro. Red indicates genes more expressed in neurons, blue in OPCs.
3Figure A-5: Difference in expression of the axon guidance pathways between astrocytes and 
neurons in rat cells in vitro, using the cross-species annotation. Red indicates genes more 
expressed in astrocytes, blue in neurons.
Figure A-6: Difference in expression of the focal adhesion pathway between astrocytes and 
neurons in rat cells in vitro using the cross-species annotation. Red indicates genes more 
expressed in astrocytes, blue in neurons.
4Figure A-7: Difference in expression of the focal adhesion pathway between astrocytes and 
OPCs in rat cells in vitro using the cross-species annotation. Red indicates genes more 
expressed in astrocytes, blue in OPCs.
Figure A-8: Difference in expression of the axon guidance pathways between neurons and OPCs 
in rat cells in vitro using the cross-species annotation. Red indicates genes more expressed in 
neurons, blue in OPCs.
5Figure A-10: The 200 genes with the 
highest expression in the experiment,
grouped by similarity of expression 
across rows. Expression by 
individual sample is shown.
Figure A-9: This heatmap shows the 
expression of the 20 most significant DEGs
in each direction for the pairwise 
comparison of astrocytes to neurons in 
humans. Data is shown for all samples.
6Figure A-11: Difference in expression of the focal adhesion pathway between in vitro and in 
vivo astrocytes. Red indicates genes more expressed in vitro, blue in vivo.
Figure A-12: Difference in expression of the focal adhesion pathway between rat and mouse 
astrocytes. Red indicates genes more expressed in rats, blue in mice.
7Figure A-13: Difference in expression of the Alzheimer's disease pathway between in vitro 
and in vivo astrocytes. Red indicates genes more expressed in vitro, blue in vivo.
Figure A-14: Difference in expression of the Alzheimer's disease pathway between rat and 
mouse astrocytes. Red indicates genes more expressed in rats, blue in mice.
8Figure A-15: Difference in expression of the axon guidance pathways between in vitro and in 
vivo settings in neurons. Red indicates genes more expressed in vitro, blue in vivo.
Figure A-16: Difference in expression of the axon guidance pathways between rat and mouse 
neurons. Red indicates genes more expressed in rats, blue in mice.
9Figure A-17: 
Difference in 
expression of the
Alzheimer's 
disease 
pathways 
between in vitro 
and in vivo 
settings in 
neurons. Red 
indicates genes 
more expressed 
in vitro, blue in 
vivo.
Figure A-18: 
Difference in 
expression of the
Alzheimer's 
disease 
pathways 
between rat and 
mouse neurons. 
Red indicates 
genes more 
expressed in 
rats, blue in 
mice.
10
Figure A-19: 
Difference in 
expression of cell 
cycle-related 
pathways between 
rat and mouse 
OPCs. Red indicates
genes more 
expressed in rats, 
blue in mice.
